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Abstract 
 
The Cullin-RING E3 ligase (CRL) family consists of over 200 enzymes that are responsible for 
the ubiquitylation and regulation of a huge variety of proteins involved in the immune 
response, cell cycle control and cell proliferation. CRLs are activated by covalent attachment 
to the C-terminus of the ubiquitin-like modifier NEDD8 by forming an isopeptide bond in a 
process called NEDDylation. Inhibition of CRLs is mediated by the COP9 signalosome complex 
(CSN) which cleaves the isopeptide bond binding to NEDD8 and removes it. CRL homeostasis 
is disrupted by CSN overactivity and is associated with the pathogenesis of ~50% of all cancers 
in humans. The means by which the activity of the catalytic subunit of CSN (CSN5) is regulated 
is not fully understood and thus new tools are required to study its activity. CSN5 contains a 
JAMM domain with a Zn2+ atom facilitating its catalytic activity. The synthesis of several 
activity-based probes for CSN5 was attempted, each containing a zinc-binding group (ZBG) 
for attachment onto the catalytic site, a NEDD8 peptide to enable selectivity to CSN5 and a 
biotin tag for subsequent biochemical assays. Three zinc-binding groups were considered 
including hydroxamic acid, imidazole and a precursor of a potent small molecule CSN5 
inhibitor, CSN5i-3. The multi-step synthesis of the CSN5i-3 precursor was attempted but not 
completed due to time constraints. In an endeavour to mimic the entire substrate of CSN5, 
the synthesis of NEDD8 was attempted but not successful. In a separate approach, a peptide 
of the NEDD8 C-terminal tail was synthesised and successfully biotinylated, however 
conjugation to the zinc-binding groups hydroxamic acid and imidazole were unsuccessful due 
to the low solubility of the peptide. 
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Chapter 1 – Introduction 
 
1.1 - Ubiquitylation 
 
Ubiquitin (Ub) is an essential small protein of ~8.5 kDa and 76 residues which is highly 
conserved and ubiquitously expressed in eukaryotic cells. Ubiquitylation refers to a reversible 
post-translational modification whereby ubiquitin is covalently transferred onto a substrate 
protein by forming an isopeptide bond between the carboxyl group of the ubiquitin C-
terminal glycine residue (Gly76) and the ε-amino group of a lysine residue on the substrate.1 
The substrate protein can be subject to the attachment of a single ubiquitin 
(monoubiquitylation) or multiple ubiquitin molecules on different residues (multi-
monoubiquitylation).2 Ubiquitin itself also contains 7 lysine residues that can act as sites of 
ubiquitylation to form extended polyubiquitin (polyUb) chains. There is diversity in ubiquitin 
chain formation such that polyUb chains can consist of linkages of the same type (homotypic 
polyubiquitylation) or linkages built up of different lysine residues (heterotypic 
polyubiquitylation).3 These ubiquitin molecules and chains act as signals that assert an array 
of cellular actions upon a substrate protein, which is dictated by the type of ubiquitin linkages. 
For example, polyubiquitin chains linked by Lys48 residues target a substrate protein for 
proteasomal degradation, a major process in protein homeostasis, whereas Lys63-linked 
polyubiquitin chains enable endocytosis of the substrate protein.4 Furthermore, the N-
terminal methionine (Met1) amino group of ubiquitin also acts a site of ubiquitylation to form 
Met1-linked linear polyubiquitin chains which play an important role in the NF-κB signalling 
pathway.5 
 
The process of ubiquitylation involves a sequential cascade of three enzymes.3 The E1 
ubiquitin-activating enzyme utilises a molecule of ATP to activate the C-terminal glycine of 
ubiquitin, which subsequently forms a thioester linkage with a catalytic cysteine residue on 
the E1 enzyme. The ubiquitin is transferred from the E1 enzyme onto the active site cysteine 
on an E2 ubiquitin-conjugating enzyme. Finally, the E2-Ub binds onto an E3 ubiquitin ligase 
which catalyses the transfer of ubiquitin onto the substrate protein to form an isopeptide 
bond (Figure 1).6 
 9 
The reverse process of ubiquitylation (ubiquitin deconjugation) is facilitated by ubiquitin-
specific proteases referred to as deubiquitylating enzymes or deubiquitinases (DUBs). These 
act to break the isopeptide bond between ubiquitin and its target protein, releasing free 
ubiquitin in the process.7 
 
 
 
 
Figure 1: The ubiquitin conjugation system consisting of the E1, E2, E3 enzymatic cascade. 
 
1.1.1 – Structural Features of Ubiquitin 
 
Ubiquitin exhibits a compact globular structure with a 5-stranded antiparallel β-sheet which 
“grasps” a 3.5-turn α-helix and a 310 helix (Figure 2A).8 This structure is collectively referred 
to as the β-grasp superfold.9 Ubiquitin also possesses a flexible C-terminal tail that protrudes 
away from the globular fold and ends with a di-glycine motif, with the distal glycine involved 
in the covalent attachment to a substrate lysine. Many proteins interact with ubiquitin non-
covalently to fulfil a cellular role and this interaction is facilitated by ubiquitin-binding 
domains (UBDs) on those proteins.10 Unlike other post-translational modifications such as 
phosphorylation, recognition of a ubiquitylated protein is not dictated by the substrate but is 
instead largely determined by regions on the surface of ubiquitin and the conformation of 
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polyUb chains.11,12 The ubiquitin surface is mostly polar with the exception of a hydrophobic 
patch located within the β-sheet consisting of residues Ile44, Leu8 and Val70. This 
hydrophobic patch is also commonly referred to as the Ile44 patch as this residue is described 
as being the centre of the area.12 The Ile44 patch is the major site of protein-protein 
interactions enabled by UBDs such as Ubiquitin Interacting Motif (UIM) and Motif Interacting 
Ubiquitin (MIU) which specifically recognise and bind to this region.10,12 For example, the MIU 
domain was first described in the interaction between ubiquitin and Rpn10, a subunit of the 
26S proteasome.13  
 
Whilst a major hotspot for protein interactions, the Ile44 patch is not the exclusive site of 
ubiquitin recognition and such interactions can also occur by other surface regions such as 
the Ile36 patch. This region is centred upon the eponymous Ile36 and consists of residues 
Leu8, Leu71 and Leu73.12,14 Likewise, other surface patches include the Phe4 patch 
(Phe4/Gln2/Thr14) and the Asp58 patch (Asp58/Arg54/Glu51) (Figure 2).15  
 
Certain UBDs may recognise and bind to multiple regions on ubiquitin. For example, the A20 
zinc finger (A20_ZnF) domain recognises both the hydrophobic Ile44 patch and the polar 
Asp58 patch. Proteins may contain multiple UBDs such as Rabex-5 which has both a UIM and 
A20_ZnF domain, thus two molecules of Rabex-5 can interact with a single molecule of 
ubiquitin by binding on two distinct regions.16,17 Furthermore, having multiple UBDs can 
enable a protein to bind polyUb chains.  
 
Depending on the linkage type, a polyUb chain may adopt a distinct conformation. For 
example, Lys48-linked polyUb chains form a compact structure whilst Lys63-linked chains 
adopt a wider, more open conformation.4,18 Likewise, the conformation of the polyUb chain 
dictates which surface regions of the ubiquitin molecules are exposed for binding. Proteins 
may contain multiple UBDs that are spaced in a way that only facilitate binding to a certain 
polyUb chain conformation. For example, Rap80 is a protein involved in DNA repair that 
contains two MIU domains that both recognise Ile44 patches. However due to spacing 
between the domains they can only bind Lys63-linked polyUb chains, thus allowing for 
selectivity in their binding.10,19 
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Figure 2: (A) Cartoon representation of the ubiquitin structure with secondary structures 
highlighted: 3.5 turn alpha helix in blue, β-sheet in orange and 310 helix in teal. (B) Structure 
of ubiquitin with its 7 lysine residues coloured in cyan, Met1 in orange and Gly76 in red. (C) 
Surface patches on ubiquitin for non-covalent protein-protein interactions. [PDB: 1UBQ] 
(Figure 2A generated in Biorender and Figures 2B-C in UCSF Chimera) 
 
 
1.1.2 – Ubiquitin-Like Modifiers 
 
The characteristic β-grasp superfold structure is not exclusively found in ubiquitin. This 
structure, along with ubiquitin’s conserved amino acid sequence, has enabled the 
identification of proteins which share structural and sequential similarities to ubiquitin, 
referred to as ubiquitin-like modifiers or ubiquitin-like proteins (UBLs).9,12 Functionally, UBLs 
are distinguished into two groups. Type I UBLs are conjugated to proteins by an ATP-
dependent enzymatic cascade consisting of E1, E2, and E3 enzymes. Therefore the 
mechanism of Type I UBL conjugation closely resembles that of ubiquitylation.20 Likewise, 
Type I UBLs possess a C-terminal tail ending in a glycine motif facilitating the covalent 
attachment onto a substrate protein. Members of this group include, but are not limited to, 
Interferon-Stimulating Gene 15 (ISG-15), Small Ubiquitin-Like Modifier (SUMO) and Neural 
Precursor Cell Expressed Developmentally Down-Regulated Protein 8 (NEDD8). In contrast, 
Type II UBLs do not engage in substrate conjugation and are instead normally found as part 
of multi-domain proteins and can facilitate non-covalent protein-protein interactions.20,21 For 
example, the E3 ligase UHRF1 contains a Type II UBL domain which, through its hydrophobic 
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patch, enables binding to an E2 enzyme UBE2D1 to form an E3-E2 complex required to 
ubiquitylate histone H3 in newly-replicated chromatin. This plays a key role in epigenetic 
regulation as the methyltransferase DNMT1 is recruited to the ubiquitylated histone to 
perform DNA methylation, thus ensuring chromatin homeostasis.22 
 
Figure 3: Structures of ubiquitin and examples of ubiquitin-like modifiers. [PDB: 1UBQ, 2N1V, 
1Z2M, 1NDD] (Figure generated in UCSF Chimera). 
 
ISG-15 
 
ISG-15 was the first protein to be identified as a UBL and was later sub-classified as a Type I 
UBL. Although first being discovered within interferon-activated cells in 1979, it wasn’t until 
1987 that it was found as a UBL when it was shown to cross-react with ubiquitin antibodies.23–
25 With a size of 17 kDa and 165 residues, ISG-15 consists of two ubiquitin-like β-grasp folds 
in tandem and structurally resembles di-Ub.26 As its name suggests, the expression of ISG-15 
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is dependent on interferon (IFN)-β and is therefore implicated in the innate immune 
response. Like ubiquitin, its conjugation to lysine residues on proteins (ISGylation) is catalysed 
be the E1-E2-E3 enzyme cascade however it occurs predominantly within the cell ribosome 
where the principal ISG-15 E3 ligase, Herc5, is localised.27 Therefore ISGylation usually occurs 
on newly-translated proteins, namely those involved in type 1 interferon (IFN-1) signalling 
which are responsible for eliciting an anti-viral response by activating immune cells such as 
macrophages and natural killer cells.23,26,27  
 
Furthermore, unlike ubiquitin, ISG-15 is conjugated exclusively as a monomer on its target 
protein and does not form polyISG-15 chains.23 ISGylation plays several key roles in the 
regulation of innate immunity. For example, the pattern recognition receptor RIG-I is a 
promoter of IFN-1 signalling and its ISGylation results in degradation by autophagy, 
consequently inhibiting IFN-1 expression which is key in preventing auto-immunity.23,28 ISG-
15 also acts to stimulate the antiviral response by prolonging the activation of proteins such 
as Interferon-Regulatory Factor 3 (IRF3) whose ISGylation prevents its ubiquitylation and 
subsequent proteasomal degradation.29  
 
Alongside stimulation of the antiviral response by conjugation onto host proteins, ISGylation 
can also occur on viral proteins, I.e. proteins produced by an invading virus itself23. This can 
interfere with the ability of viral proteins interact with each other or with host proteins. For 
example, the influenza A protein NS1 (NS1A) interacts with and supresses the host enzyme 
Protein Kinase R (PKR) which plays a role in antiviral defence. ISGylation of NS1A on Lys-41 
blocks this interaction with PKR and thus prevents the suppression of PKR-mediated host 
defence.26,30,31 
 
Interestingly, to combat this response, viruses have evolved to encode for DUBs which act to 
deconjugate ISG15 from their proteins. For example, Severe Acute Respiratory Syndrome-
Related Coronavirus (SARS-CoV) was amongst the first viruses discovered to contain DUBs 
which deconjugate ISGylated proteins.23,32 SARS-CoV papain-like protease (PLP) shows 
selectivity towards ISG15 and it has been demonstrated that PLP deconjugates ISG15 from 
IRF3 to supress IFN1 signalling.33  
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SUMO 
 
Although ISG-15 was the first UBL to be discovered, it is still not relatively well-studied. In 
contrast, SUMO is the most extensively researched and characterised UBL.12 The SUMO family 
of proteins consists of 4 isoforms in mammalian cells, three of which are physiologically active 
(SUMO-1, -2 and -3) and a fourth (SUMO-4) which is the least studied isoform and is not 
known to be functional under physiological conditions.34 At 11 kDa and 100 residues, SUMO 
contains the characteristic structural β-grasp superfold which resembles that of ubiquitin and 
has a C-terminal di-glycine motif to facilitate substrate conjugation. However SUMO has an 
extended flexible N-terminal region, making it larger than and structurally and functionally 
distinct from ubiquitin.35,36  
 
SUMO exhibits a highly diverse role in cellular homeostatic processes, including cytosolic 
transport, transcriptional regulation and DNA repair. However, unlike ubiquitin, it is not 
directly involved in the targeting of proteins for degradation.34,37 SUMOylation refers to the 
reversible C-terminal conjugation of SUMO onto a lysine residue of a substrate protein by 
forming an isopeptide bond. Just like other Type I UBLs, SUMOlyation utilises the ATP-
dependent E1-E2-E3 conjugation pathway.34 The removal of SUMO from its substrate, 
deSUMOylation, is performed by SUMO-specific proteases (SENPs) which target specific 
SUMO isoforms and cleaves the isopeptide bond with the substrate.38 A well-researched 
example of SUMOylation is that of the DNA-repair response enzyme Thymine DNA 
Glycosylase (TDG) which binds to and excises mismatched G-U and G-T base pairs within 
damaged DNA. Following excision, the enzyme binds with high affinity to the repaired DNA 
and cannot continue its repair cycle. SUMOlyation of TDG assets a conformational change 
which releases it from the DNA and, following deSUMOylation, the enzyme can continue to 
bind to mismatched bases and repair DNA mutations.34,35,37 
 
NEDD8 
 
At 8.5 kDa and 76 residues, NEDD8 is the closest relative to ubiquitin and, amongst other 
UBLs, shares the greatest structural similarity to ubiquitin. With its C-terminal di-glycine 
motif, NEDD8 can be conjugated to substrate lysine residues in a process referred to as 
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NEDDylation.39,40 The gene NEDD8 encodes for an 81-residue precursor protein that is 
deemed inactive. Processing of NEDD8 involves cleavage of 5 residues from the C-terminus 
to generate the di-glycine motif. This proteolytic step is performed by the cysteine protease 
deneddylase 1 (DEN1) which forms the mature 76-residue NEDD8 protein.41,42 The 
conjugation of NEDD8 onto a substrate lysine is facilitated by the E1-E2-E3 enzymatic cascade 
analogous to ubiquitin and other Type I UBLs. NEDD8-Activating Enzyme (NAE), a heterodimer 
consisting of amyloid-β precursor protein-binding protein 1 (APPBP1 or NAE1) and ubiquitin-
activating enzyme 3 (UBA3), is the only known NEDD8-specific E1.43,44 Following activation by 
NAE, NEDD8 is transferred onto one of two NEDD8-conjugating E2 enzymes, UBE2M (also 
known as UBC12) or UBE2F.43 Subsequently, NEDD8 is transferred onto an E3 ligase which is 
responsible for conjugation of NEDD8 onto a substrate protein. Whilst there is a variety of 
E3s which can target both ubiquitin and NEDD8, there is only one E3 specific for NEDD8, a 
complex consisting of the ligases Defective in Cullin Neddylation Protein 1 (Dcn1) and RING 
box protein 1 (Rbx1).45,46 
 
NEDD8 shares a high percentage of amino acid sequence homology to ubiquitin, with ~58% 
sequence identity and ~77% sequence similarity.43 A sequence comparison between NEDD8 
and ubiquitin reveals that many residues essential for ubiquitin function are conserved within 
NEDD8 (Figure 4). For example, lysine residues are largely conserved between the two 
proteins and allow for NEDD8 to form polymeric chains.47 Although the biological role of these 
poly-NEDD8 chains has yet to be ascertained. Similarly, the residues Ile44, Leu8, His68 and 
Val70 are conserved in NEDD8 and these make up the canonical Ile44 hydrophobic patch seen 
in ubiquitin.43 Being the major site of non-covalent interactions, the Ile44 patch also serves as 
a key-binding site for protein-protein interactions in NEDD8. Likewise, the Ile36 patch 
consisting of residues Ile36, Leu8, Leu71 and Leu73 is also conserved in NEDD8 and serves as 
another means of forming non-covalent protein-protein interactions.14,43  
 
On the contrary, sequential differences between the two proteins allow for differentiation 
between binding partners. Lys63 is a key site for ubiquitin-chain formation with significant 
biological function, however in NEDD8 this position is occupied with a glycine residue and 
therefore lacks this important conjugation site.43 Like ubiquitin, the surface of NEDD8 is 
largely polar with the exception of the conserved hydrophobic patches. The main regions of 
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divergence between NEDD8 and ubiquitin are observed as clustered areas on the surface of 
the molecules.48 NEDD8 contains a region of charged residues (Lys22, Arg25, Glu28, Glu31) 
whereas in ubiquitin this region is uncharged (Thr22, Asn25, Ala28, Gln31).  
 
Another main region of divergence is a cluster containing nonpolar and charged residues on 
NEDD8 (Lys4, Glu12, Glu14, Gly63 and Gly64) whilst in ubiquitin these positions contain 
residues Phe4, Thr12, Thr14, Lys63 and Glu64. A small site of divergence is an area containing 
Asn51 and Glu53 in NEDD8 which are polar and charged, respectively, whereas in ubiquitin 
these sites are occupied by Glu51 and Gly53 which are, respectively, charged and nonpolar. 
Lastly, Arg72 in the ubiquitin C-terminal tail is occupied by an alanine residue in NEDD8 (Figure 
5).43 Collectively, whilst possessing highly similar structures, these sites of divergence allow 
for the discrimination between NEDD8 and ubiquitin by their respective conjugation and 
deconjugation enzymes.43 These differences are important as, whilst ubiquitylation occurs on 
most eukaryotic proteins, NEDD8 is significantly less promiscuous and is conjugated onto a 
significantly smaller number of substrates which are mostly members of the Cullin family of 
scaffolding proteins.49 
 
Figure 4: Alignment of human ubiquitin and NEDD8 protein sequences with divergences 
highlighted in red within the NEDD8 sequence. Performed using NCBI BLAST.50,51 
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Figure 5: Structures of ubiquitin and NEDD8 with clusters of divergence coloured in red. 
[PDB: 1UBQ, 1NDD] (Figure generated in UCSF Chimera) 
 
For example, the E1 enzyme NAE needs to distinguish between NEDD8 and ubiquitin for its 
activation. This is achieved by recognition of residues in the flexible C-terminal tail.44 Upon 
docking to NAE subunit UBA3, a conformational change in the NEDD8 C-terminal tail allows 
for the residues Leu71 and Ala72 to bind with Leu206 and Tyr207 within UBA3.43,52 The main 
difference between the NEDD8 and ubiquitin C-terminal tail is a single residue in position 72 
which is essential in the specific recognition of NEDD8. In this connection, it has been 
demonstrated that a mutation of Ala72 in NEDD8 to Arg impedes this specificity for UBA3 
binding to NEDD8.  
 
Furthermore, repulsion of Arg72 is mediated by Arg190 in the UBA3 binding site.52 Therefore, 
even small divergences between the NEDD8 and ubiquitin sequences can lead to key 
differences in enzyme recognition. In contrast, the similarity between the two proteins can 
lead to crosstalk between their pathways and shared recognition by enzymes. The ubiquitin-
activating E1 enzyme UBE1, for example, is able to recognise and activate NEDD8 under 
conditions of cellular stress to help alleviate the relevant stress response.53 However this is 
kinetically slow and unfavourable, therefore NEDDylation by ubiquitin-specific enzymes is 
uncommon but not impossible.43 
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Whilst conjugation of NEDD8 by ubiquitylation machinery is unfavourable, binding of NEDD8 
to UBDs is very common. Due to the presence of the Ile44 hydrophobic patch on NEDD8 which 
is conserved from ubiquitin, UBDs can bind to both and many show little preference between 
the two proteins.54 Whilst the UBA ubiquitin-binding domain in RAD23, a ubiquitin carrier, 
has a greater affinity for ubiquitin over NEDD8, the protein ubiquilin-1 has no preference for 
ubiquitin over NEDD8.43,55 Likewise, in addition to ubiquitin binding, Epidermal growth factor 
receptor substrate 15 (EPS15) also binds NEDD8 via its UIM motif.56 The ability for a protein 
UBD to distinguish between ubiquitin and NEDD8 is not yet understood.  
 
Recently, phage lambda display of a human brain cDNA library has revealed a novel binding 
domain in the protein KHNYN named CUBAN (Cullin-Binding domain Associating with 
NEDD8).54 This domain is unique due to its preference for NEDD8 binding over ubiquitin, a 
trait not seen in other UBDs. Furthermore, it has been demonstrated that binding of NEDD8 
to the CUBAN domain requires the NEDD8 to be conjugated onto a cullin-family protein. 
Structural insights into the CUBAN-NEDD8 interaction were determined by NMR spectroscopy 
and it was revealed that positively charged His and Arg residues in CUBAN bind to NEDD8 at 
residues Ile13 and Glu14 in the 2nd β-strand and polar residues Glu31, Glu32, Lys33, Glu34 in 
the α-helix.54 Therefore, rather than a hydrophobic interaction, the CUBAN domain interacts 
with NEDD8 in an electrostatic manner.43 
 
 
1.1.3 – Ubiquitin Conjugation: E3 ligases 
 
There exists over 600 E3 ligases in the human proteome which perform the conjugation of 
ubiquitin and UBLs to their target.57 These E3s are functionally classified based on their 
mechanism of conjugation and the presence of characteristic structural domains. There are 
two major types of E3s, HECT and RING, which have distinct ubiquitylation machinery. 
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HECT E3s 
 
HECT E3s were the first class of E3 ligases to be discovered and there are 28 known HECT E3 
ligases in humans.58 The enzyme consists of two components, the N-terminal substrate 
binding domain (N-lobe) which is attached by a hinge to the C-terminal HECT domain (C-lobe) 
which contains a catalytic cysteine residue.59 Ubiquitylation by HECT E3s is carried out in a 
two-step process. The N-lobe acts as docking site for the E2-Ub thioester and binds onto the 
E2 enzyme. Once docked, the Ub is transferred from the E2 onto the catalytic cysteine on the 
C-lobe by transthiolation. In a second step, ubiquitin is transferred from the HECT domain 
onto the substrate protein where it forms an isopeptide bond with a lysine residue on the 
substrate.60 The flexible hinge region allows the lobes to orient themselves in a manner that 
ubiquitin transfer onto the substrate is optimal.60,61 
 
RING E3s 
 
With ~600 members, the RING class of E3 ligases are the most abundant.59 These E3s are 
characterised by the presence of a RING finger domain, which is made up of 8 cysteine and 
histidine residues coordinating two zinc ions in a cross-braced structure.62 Unlike HECT 
domains, the RING domain is not inherently catalytic and lacks a cysteine residue to mediate 
transthiolation with ubiquitin. Instead, RING E3s act as an adaptor which binds the E2-Ub 
thioester and juxtaposes it with respect to the substrate to mediate the direct transfer of 
ubiquitin from the E2 onto the substrate protein.63 
 
Cullin-RING E3s (CRLs) 
 
Within the RING E3 family exists sub-families, with the largest consisting of over 200 members 
known as the Cullin-RING E3 ligases (CRLs).64 CRLs exist as multiprotein complexes consisting 
of four main components, a RING finger domain for E2-Ub thioester binding, a substrate 
recognition domain, adaptor proteins and a cullin which acts as an overall scaffold for the CRL 
complex. Each component of the complex is variable and can form many different 
combinations, leading to a large number of CRLs being expressed and consequently a high 
degree of substrate specificity.65  
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There are seven members of the cullin family of proteins expressed in mammals (CUL1, CUL2, 
CUL3, CUL4A, CUL4B, CUL5 and CUL7), named after their involvement in selecting or “culling” 
proteins for ubiquitin-mediated degradation by the proteasome.66 The C-terminal winged 
helix B (WHB) domain of the cullin binds to one of two RING domains, RING Box Protein (Rbx)-
1 or Rbx2. The N-terminal region of cullin interacts with an adaptor protein used to link the 
substrate recognition domain with the rest of the CRL complex. The adaptor protein can be 
one of Skp1, Elongin-C, BTB and DNA damage binding protein 1 (DDB1), amongst others.64 
Substrate specificity of the CRL is determined by the specific substrate recognition protein in 
the complex, such as F-box proteins, VHL-box, SOCS-box, DCAF etc.65 
 
The best characterised CRL is CRL1, which is also commonly referred to as the SCF (Skp1-Cul1-
F-box) complex.65 Cul1 acts as the scaffold for the complex, with RING domain Rbx1 bound to 
its C-terminal region and the adaptor Skp1 bound on the N-terminus.64 Skp1 is used to 
facilitate the attachment of the substrate receptor F-box with the rest of the complex. The 
specific F-box protein of the SCF is variable, with the three most well-studied being Skp2, 
FBXW7 (F-box WD40 repeat-containing protein-7) and β-TrCP (β-transducin repeat-
containing protein).65 For example, SCFβ-TrCP plays a key role in the DNA damage response by 
targeting cell-cycle proteins Cdc25 and Wee1 for ubiquitylation and proteasomal 
degradation. Degradation of these proteins results in inhibition of G1/S-phase progression 
and G2/M entry to mitosis to ultimately halt the cell cycle during DNA damage.67 
 
Activation of CRLs to allow for ubiquitylation of a substrate requires the E3 itself to undergo 
a post-translational modification, whereby the C-terminal domain of cullin (Lys720 in Cul1, 
for example) must undergo NEDDylation.64,68 NEDDylation of cullin induces a conformational 
change between the cullin WHB-Rbx interface whereby the Rbx protein, which is interacting 
with E2-Ub thioester, dissociates from cullin and positions itself towards the protein 
substrate, allowing close interaction with E2-Ub and subsequent ubiquitylation of the 
substrate to occur.69 Inhibition of CRL E3 ligase activity is performed by deneddylation of the 
cullin by the COP9 signalosome, which is discussed in greater detail in chapter 1.2.70 
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Figure 6: (A) Cullin Ring Ligase (CRL) complex in its inactive state. (B) Neddylation of CRL on 
the C-terminal WHB domain of cullin enables a conformational change in the complex 
allowing E3 activity and ubiquitylation. 
 
1.1.4 – Ubiquitin Deconjugation: DUBs 
 
Protein ubiquitylation (and covalent attachment of UBLs) is a reversible process. The removal 
of ubiquitin from a substrate by cleavage of the isopeptide bond (deubiquitylation) is 
catalysed by a group of isopeptidases known as deubiquitinases (DUBs). Deubiquitylation has 
a diverse set of functions, including the editing of polyUb chains, maturation of newly 
synthesised ubiquitin and regulation of cellular processes.71 Whilst proteins are targeted for 
proteasomal degradation by being polyubiquitylated on Lys48 residues, the 26S proteasome 
itself requires the target protein to be cleared of all ubiquitin molecules before degradation 
can occur.72 Importantly, deubiquitylation releases free ubiquitin which can be recycled for 
further use, thus ensuring that the cell retains an abundance of ubiquitin.73 There are two 
main classes of DUBs differentiated based on their mechanism of action, cysteine/thiol DUBs 
and metalloDUBs. There are currently six known families of thiol DUBs, Ubiquitin C-terminal 
Hydrolase (UCH), ovarian tumour proteases (OTU), Ubiquitin-Specific Proteases (USP), 
Josephin, MIU-containing Novel DUB family (MINDY) and, most recently discovered, 
ZUFSP/ZUP1. Meanwhile there exists only a single family of metalloDUB, JAB1/MPN/MOV34 
metalloenzymes (JAMM).74 
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The ubiquitin recognition/binding site on a DUB is referred to as the S1 site which, like UBDs, 
binds to hydrophobic patches on ubiquitin.75 Since NEDD8 also contains these surface 
patches, DUBs can distinguish it from ubiquitin in a similar manner to E1, E2 and E3 enzymes, 
I.e. due to Ala72 in the C-terminus. DUBs which cleave polyUb chains contain another binding 
site called the S1’ site. In the case of diUb, the distal ubiquitin binds onto the S1 site and the 
proximal ubiquitin to the S1’ site.76,77 DUBs can contain further interaction sites such as S2, 
S2’, S3 etc which mediate binding to polyUb chains.76 The S1’ site is key in determining linkage 
specificity in the cleavage of polyUb chains as the exact orientation of the proximal ubiquitin 
affects the lysine residue presented to the catalytic site. The S1’ site can also be located on 
binding partners of the DUB.75 For example, the JAMM-family DUBs AMSH and AMSH-LP have 
low intrinsic DUB activity until they bind with Signal Transducing Adaptor Molecule (STAM).78 
STAM contains a UIM domain which interacts with the proximal ubiquitin of Lys63-linked diUb 
and thus the AMSH-STAM complex is specific for this chain type.75,79 
 
Thiol DUBs 
 
Thiol DUBs are named as such since they contain a cysteine residue in their catalytic site. The 
catalytic site is made up of a triad of three residues, cysteine, histidine and an acidic residue 
(e.g. aspartic acid in USP family DUBs). In the triad, the thiol group of cysteine is deprotonated 
by histidine. Following binding of ubiquitin to the S1 site, the deprotonated thiol performs a 
nucleophilic attack upon the carbonyl group of the isopeptide bond. This forms a negatively 
charged tetrahedral intermediate which is stabilised by an oxyanion hole at the carbon. The 
intermediate subsequently collapses and the isopeptide bond is hydrolysed. At this point, if 
the DUB is cleaving a diUb, the proximal ubiquitin is released from the S1’ site. An acyl 
intermediate is formed on the (distal) ubiquitin at the S1 site. Deacylation by water is 
performed on this site and another oxyanion hole is formed, which hydrolyses the bond with 
cysteine and releases the ubiquitin from the S1 site, subsequently allowing the regeneration 
of the catalytic triad (Figure 7).75 
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Figure 7: Catalytic mechanism of thiol DUBs, with USP as an example. Hydrogen bonds are 
represented by yellow dotted lines. Reproduced from Mevissen et al.75  
 
MetalloDUBs 
 
JAMM family DUBs do not contain a cysteine in the catalytic site. Instead, the catalytic 
mechanism is dependent on a zinc atom in the active site, which is coordinated by two 
histidines, an acidic residue and a water molecule. Following binding of ubiquitin to the S1 
site and, in the case of polyUb, the S1’ site, the hydroxyl group of the water molecule, 
following activation, performs a nucleophilic attack on the carbonyl carbon of the isopeptide 
bond and forms a tetrahedral intermediate. Following collapse of the intermediate and 
hydrolysis, the isopeptide bond is broken and both ubiquitins are released at the same time. 
Subsequently, the catalytic site is regenerated (Figure 8).75 
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Figure 8: Catalytic mechanism of JAMM family metallo DUBs, with AMSH-LP as an example. 
Hydrogen bonds are represented by yellow dotted lines. Reproduced from Mevissen et al.75 
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1.2 – The COP9 Signalosome 
 
The COP9 Signalosome (CSN) is a vital eukaryotic multiprotein complex that plays a key role 
in ubiquitin homeostasis by acting as a deneddylase. The CSN isopeptidase activity is 
specifically directed towards the cleavage of NEDD8 from cullins within CRL E3 ligases, which 
subsequently deactivates them. Unlike other isopeptidases, CSN activity is specific for 
NEDDylated cullins and does not cleave NEDD8 conjugations to other proteins nor 
ubiquitin/UBL conjugations. 
 
1.2.1 – CSN Structure 
 
The human CSN complex is composed of eight subunits (CSN1-8), all of which are required for 
full in vitro activity of the enzyme (Figure 9).80 Two of these subunits contain JAMM domains 
(CSN5 and CSN6) and the other six subunits have PCI (proteasome lid-CSN-initiation factor) 
domains. X-ray crystallography has revealed that the 6 PCI domain subunits assemble into a 
horseshoe-like ring while CSN5 and CSN6 form a heterodimeric complex.81 The main function 
of the PCI subunits is to provide a structural scaffold for the complex while the CSN5-CSN6 
heterodimer is involved in catalytic activity.81,82 The C-terminal α-helices of each subunit are 
united to form a helical bundle over the PCI ring, upon which the CSN5-CSN6 heterodimer sits 
and is slightly juxtaposed from the rest of the complex. Therefore the overall structure of CSN 
is a three-tier assembly consisting of the PCI ring, helical bundle and JAMM dimer.81–83  
 
The structure of CSN is similar those of the 19S proteasome lid and the eukaryotic translation 
initiation factor (eIF3) which also contain JAMM and PCI domains and are arranged in a three-
tier complex.80,84 Furthermore, CSN2 and CSN4 recruit NEDDylated cullins of CRLs to the CSN 
complex to allow for the cleavage of NEDD8.81 Whilst both CSN5 and CSN6 contain JAMM 
domains, only CSN5 has an active domain with a zinc atom required for metalloprotease 
activity, therefore CSN5 acts as the catalytic site within the CSN.81 However, deletion of CSN6 
severely impairs CSN5 catalytic activity, suggesting that CSN6 plays a role in stabilising the 
CSN5 JAMM domain to allow it to function.81,82 
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Figure 9: Molecular model of the human COP9 signalosome complex bound to NEDDylated 
cullin, based on cryo-electron microscopy (cryo-EM). Figure taken from Mosadeghi et al.85 
 
1.2.2 – CSN5 Activation 
 
Within inactive CSN, the JAMM motif of CSN5 consists of a Zn2+ ion coordinated by two 
histidine residues (His138 and His140), Asp151 and a Glu104.81 An active JAMM domain 
requires a water molecule coordinating the zinc atom, however within inactive CSN5, this 
water is replaced with Glu104 of the insertion-1 (Ins-1) loop segment of CSN5.81,86 In this 
conformation, the Ins-1 loop covers the active site and prevents it from binding to substrate 
isopeptide bonds and thus the enzyme is in an autoinhibited state.81 Furthermore the active 
site water is coordinated and polarised by an acidic Glu76 residue in CSN5.81,87 Therefore, in 
order for CSN5 to become active, Glu104 needs to be removed from the catalytic site, the Ins-
1 loop must undergo a conformational shift to open up the active site and Glu76 must activate 
the catalytic water molecule (Figure 10).81 
 
It has been evidenced that activation of CSN5 requires binding of a NEDDylated CRL to the 
CSN complex. Once binding has occurred, a significant conformational change in CSN5 causes 
the Ins-1 loop to swing out to reveal the active site. Conformational shift of the Ins-1 loop 
subsequently removes Glu104 from the catalytic cleft and allows water to be coordinated 
within the active site to facilitate isopeptidase activity.81,87 
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Studies using electron microscopy have revealed that, following binding of CSN2 to the C-
terminal WHB of NEDDylated cullin, CSN4 undergoes a conformational rotation in its N-
terminus.81,88 Within the CSN complex, CSN4 interacts with the JAMM domain of CSN6 
through a conserved β-hairpin loop in CSN6 called the Ins-2 loop. A conformational change in 
CSN4 proceeding cullin binding induces a change in the Ins-2 loop of the CSN6 JAMM domain, 
which enhances the CSN5-CSN6 dimer interaction and allows the CSN5 JAMM domain to be 
stabilised.81 A CSN6 mutant which lacks Ins-2 loop residues was used to elucidate the specific 
role of the CSN4-CSN6 interaction. It was revealed that in this mutant, the enzyme had a 
higher activity than wild type CSN. Furthermore, the CSN6 mutant was used to study 
specificity of the CSN complex towards NEDD8 by surveying the ability of the mutant to cleave 
an artificial DUB substrate, rhodamine-ubiquitin. Whilst wildtype CSN does not cleave the 
rhodamine-ubiquitin, the CSN6 mutant complex lacking the Ins-2 loop was able to cleave the 
isopeptide bond with a Km of 1.8 µM.81 Therefore it is proposed that the specificity of CSN 
isopeptidase activity towards NEDDylated CRLs is due to the CSN4-CSN6 interaction and, once 
this interaction is mutated, CSN5 is able to act as a more promiscuous isopeptidase.81 
 
Due to the fast rate of isopeptidase activity, an X-Ray structure of the CSN5-NEDD8 complex 
has not been solved. This is due to NEDD8 being rapidly released from the complex following 
cleavage of the NEDD8-cullin isopeptide bond.85,89 Therefore, whilst the major sites of 
protein-protein interactions between NEDD8 and CSN5 are the C-terminus and, most likely, 
the Ile36 patch of NEDD8 due to its close proximity to the C-terminus, there is little structural 
information to analyse these interactions and any other potential interactions between the 
complex. Cryo-EM structures of the complex have been solved however these are at a 
relatively low resolution, thus a high-resolution X-Ray structure would enable further 
structural analysis of the complex. 
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Figure 10: The catalytic JAMM site of CSN5. (A) CSN5 is autoinhibited with the Ins-1 loop 
blocking access of the site to water for activity. (B) In its catalytically active conformation, the 
Ins-1 loop (yellow) is shifted to allow coordination of water to the JAMM site. Images taken 
from Mosadeghi et al. based on cryo-EM structures.85 
 
1.2.2 – Cellular Roles of CSN Activity 
 
CRLs perform the ubiquitylation of proteins involved in a huge variety of key cellular functions 
such as immune response, cell cycle control, cell proliferation and stress pathways.90 The 
regulation of CRLs is vital to ensure the adequate homeostasis of these cellular pathways and 
maintain a healthy cell. By deneddylating CRLs, CSN acts to inhibit these E3s and negatively 
regulate their activity. Therefore, CSN plays a vital role in maintaining cellular and proteome 
homeostasis. 
 
For example, the aforementioned SCF complex ubiquitylates key players in the cell cycle for 
their degradation and thus halts cell cycle progression during DNA damage.91 However, 
overactivity of the SCF can prevent cell cycle progression and impede cell division.65 Likewise, 
other substrates of the SCF include oncoproteins such as c-Jun and β-catenin and tumour 
suppressors including p21, p27, and NF1.65,92,93 Abnormal overactivation of SCF has been 
found in several cancers in humans.94 Similarly, CRL4 also targets DNA damage response 
proteins such as the DNA replicating factor CDT1 and XPC alongside regulators of histone 
methylation such as the Histone-Lysine N-methyltransferase PR-Set7.65,95 Thus CRL4 is 
involved in regulating DNA replication and chromatin modifications. Just like SCF, in human 
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cancers abnormal activation of CRL4 has been observed.96 Therefore, it is vital that the CSN 
negatively regulates CRL activity to prevent cancer progression and maintain cell 
homeostasis. 
 
Moreover, CSN asserts cellular roles indirect of its isopeptidase activity. For example 
immunoprecipitation analysis has shown that CSN3 within the CSN complex acts as a docking 
site for protein kinases such as Protein Kinase D (PKD) and casein kinase 2 (CK2) which 
phosphorylate tumour suppressor p53, transcription factor c-Jun and also CSN7.97 
Furthermore, CSN also associates with the DUB USP15 to deubiquitylate IκBα within the NF-
κB signalling pathway, a vital regulator of the innate and adaptive immune response.98 IκBα 
acts as an inhibitor of NF-κB by tethering it to the cytoplasm of the cell where it is inactive. 
Following phosphorylation by IkB Kinase (IKK) complexes, IκBα is ubiquitylated by SCFβ−TrCP for 
its degradation, allowing NF-κB to translocate to the nucleus and become active as a 
transcriptional factor to mediate inflammation during an immune response. Not only does 
CSN deneddylate SCFβ−TrCP and prevent further ubiquitylation, it binds with USP15 which 
cleaves ubiquitin from IκBα to allow its rapid replenishment and consequently inhibit NF-κB 
translocation.98 
 
Interestingly, it has emerged that CSN5 also directly interacts with IKK complexes. Alongside 
phosphorylating IkBα for its subsequent ubiquitylation, IKK also phosphorylates CSN5 on 
Ser201 and Thr205 and this has been shown to attenuate CSN5 deneddylase activity, allowing 
for IkBα degradation and NF-κB translocation.99,100 This was determined by generating 
phospho-mutants of CSN5 and determining its deneddylation activity for NEDD8-Cul1. It was 
shown that the mutant generates less free Cul1 than the wildtype enzyme, suggesting that 
the mutant CSN5 exhibits less deneddylation activity, however some activity still persists.99 It 
has also been shown that treatment with IKK activator TNF-α results in increased interaction 
of CSN with CRL5 and proteasomal DUBs, but the effects of these interactions downstream of 
TNF-α activation have not yet been studied.99 
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1.2.3 – CSN in Disease Pathogenesis 
 
Dysregulation of CSN has been associated within the pathology of several diseases. In 
particular, CSN5 overexpression is seen in a variety of cancers as it has been evidenced to 
positively regulate oncogenes and negatively regulate tumour suppressors.101 Most notably, 
low levels of the cyclin-dependent kinase inhibitor p27, which is a tumour suppressor, are 
seen in ~50% of cancers and this downregulation is correlated with CSN5 activity.102 CSN5 is 
implicated in the translocation of p27 from the nucleus to the cytoplasm and thus inhibits its 
antiproliferative effects, resulting in cell proliferation and tumour progression.103 
 
Moreover, the tumour suppressor p53 is activated in response to DNA damage and acts as a 
transcription factor to express downstream genes such as p21 which inhibit the cell cycle and 
halt cell proliferation, thus preventing cancer progression.104 The RING E3 ligase Murine 
Double Minute 2 (MDM2) regulates p53 activity by targeting it for ubiquitylation and 
proteasomal degradation.105 It is extremely important that correct levels of p53 are 
maintained in the cell as p53 accumulation can induce apoptosis whereas under expression 
leads to tumour progression.106,107  
 
Phosphorylation of p53 by ataxia telangiectasia mutated (ATM) hinders its binding to MDM2 
and prevents its ubiquitylation, while MDM2 phosphorylation by ATM destabilises its RING 
domain and inhibits its activity.108,109 Both of these phosphorylation events ultimately allow 
for p53 accumulation in the DNA damage response. However, CSN5 has been implicated in 
the stabilisation of MDM2 and subsequent degradation of p53, thereby allowing tumour 
progression and cancer pathophysiology.110 The exact mechanism for this MDM2 activation 
is unclear but may be associated with the stabilisation of its upstream enzymes by means of 
protecting them from ubiquitylation by CRLs. 
 
Vascular smooth muscle cells (VSMCs) are a major component of blood vessels and, in healthy 
vessels, exhibit low levels of proliferation and differentiation.111 However under pathological 
conditions there is increased proliferation of these VMSCs which is implicated in the 
development of vascular diseases such as atherosclerosis and pulmonary/systemic 
hypertension, and also in cancer.90 SCF ubiquitylates cell division cycle 25A (CDC25A) and 
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targets it for degradation.112 CDC25A is known to positively regulate the cell cycle and enable 
increased cell division.113 Therefore increased CSN activity leads to accumulation of CDC25A 
and it has been hypothesised that this leads to increased proliferation of VSMCs.90 
 
The CSN5 gene only rarely undergoes mutations.101 Therefore it is not clear how CSN5 
overexpression occurs and whether there is an upstream enzyme regulating CSN5 activity and 
expression. Whilst CSN interacts with proteins such as Myc, USP15 and protein kinases, it is 
not currently known whether these proteins modulate CSN5 activity.114 Therefore further 
investigations into CSN5 activation and expression are essential for pharmacological 
intervention and drug discovery. 
 
1.2.4 – CSN5i-3 
 
As the catalytic centre of CSN activity, CSN5 is a viable drug target for inhibition of the CSN 
complex. High-throughput screening of compounds against CSN5 and subsequent 
optimisation allowed for the development of the first small-molecule inhibiter of CSN5, 
named CSN5i-3 (Figure 11).115 This molecule acts as a zinc chelator and binds to the zinc atom 
within the JAMM domain of CSN5 in a monodentate manner. This zinc chelating property is 
achieved through the imidazole ring in the molecule. Specificity towards CSN5 is 
accomplished due to an amide-linked region of the molecule that extends to the active site 
cleft of CSN5, as revealed by the co-crystal structure determined by X-Ray diffraction (Figure 
11). Moreover, CSN5i-3 is the first example of a JAMM-family DUB inhibitor. CSN5i-3 potently 
inhibits CSN5 and has an IC50 of 5.8 nM. The small molecule is also specific for CSN5 inhibition 
and does not show affinity towards other tested JAMM family proteases, such as AMSH-LP 
which is structurally the most similar DUB to CSN5.115 However, the selectivity of CSN5i-3 for 
CSN5 has not been tested against the JAMM-family DUBs BRCC36 and MYSM1.  
 
 32 
 
 
Figure 11: CSN5i-3 with a model of it bound to the catalytic Zn2+ atom of CSN5. Figure taken 
from Schlierf et al.115 
 
1.3 – Activity Based Probes 
 
1.3.1 – The Need for Tools to Study Enzyme Activity 
 
Many enzymes in the cell are members of larger signalling pathways, leading to their tight 
regulation that is necessary to maintain proteome homeostasis. The dysregulation of 
enzymes is a major contributor to disease pathology and therefore many drugs act to restore 
this homeostasis by activating or inhibiting these enzymes.116 Therefore it is important to 
have tools and methods to study enzyme activity, however this can be difficult, especially in 
enzymes that are subject to posttranslational modifications for regulation of their activity.117  
 
A large number of protein studies are performed by means of measurement of mRNA levels 
or protein abundance, however this is not a feasible way of studying protein activity. Many 
proteases, for example, are found in an autoinhibited state and must undergo activation 
before they are enzymatically functional.117 So, whilst an enzyme may be abundant in a cell, 
its expression does not correlate with its activity and therefore these aforementioned studies 
will not provide any quantitative information on enzyme activity. Many studies instead focus 
on the abundance of an enzyme’s target substrate. However, this is a highly indirect approach 
as proteins can be subject to regulation by a plethora of different enzymes, therefore these 
studies can provide highly ambiguous data and non-robust conclusions.117 
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Activity-based probes (ABPs) have emerged as powerful tools in the study of enzyme activity. 
ABPs irreversibly bind onto the catalytic site of an enzyme only in its active state and their 
binding can be monitored to quantify enzyme activity. ABPs covalently label enzymes of 
interest in an activity-dependent manner. There are 3 components of an ABP: a reactive group 
referred to as a warhead; a recognition element; a reporter tag.118 
 
1.3.2 – Components of an Activity Based Probe 
 
Warhead 
 
Labelling of an ABP to the enzyme active site is achieved through the warhead which targets 
the catalytic component of the enzyme. This is normally an electrophile on the probe which 
reacts with an active site nucleophile on the target.119 Where this reactivity is not possible, a 
photocrosslinking approach can by utilised whereby a UV-sensitive linker on the probe forms 
a radical intermediate when stimulated with UV light and can form covalent bonds with the 
target enzyme.120 Enzymes which contain metals in their active site can also be targeted with 
a metal-binding moiety or photocrosslinker.118 It is important that the warhead is able to 
reach the active site in close proximity to facilitate binding. As such, it is key that the other 
components of the ABP do not interfere with the ability of the warhead to closely interact 
with the target with appropriate geometry. For example, a bulky recognition element may 
hinder the ability for the warhead to bind to the target. 
 
Recognition Element 
 
Whilst the warhead attaches the probe onto a catalytic site, it does not provide selectivity for 
a certain enzyme. Therefore, a second component, the recognition element, acts to direct the 
ABP towards a specific enzyme or class of enzyme by possessing affinity for the enzyme.117 
This is usually accomplished with the use of peptides which mimic a portion of the substrate, 
a protein domain or a whole protein. A major caveat with the recognition element is the poor 
cell permeability of many peptides and proteins.121 Accordingly, many ABP studies are limited 
to cell lysates unless the issue of cell permeability is addressed. The incorporation of a cell-
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penetrating peptide (CPP), a short peptide consisting of basic residues (lysine and arginine) 
onto the recognition element has been used for ABPs in proteomic studies.122,123 
 
Furthermore, it is important when designing an ABP to consider both the reactivity of the 
warhead and selectivity of the recognition element. A highly reactive warhead coupled with 
a low affinity recognition element may not provide significant selectivity due to promiscuity 
of the warhead. However, if coupled with a high affinity recognition element, then the 
reactivity of the warhead likely will not hinder probe selectivity. Likewise, a low reactive 
warhead combined with a high affinity recognition element will provide high selectivity but 
the efficiency of probe labelling will be reduced.124 
 
Reporter Tag 
 
A key feature of the ABP which differentiates it from an enzyme inhibitor is the attachment 
of a reporter tag which facilitates detection of probe labelling and quantitative enzyme 
activity assays. The choice of reporter tag is dictated by the desired probe labelling assay or 
study, i.e. ABP target identification or ABP target validation.125 Affinity labels such as epitope 
tags, for example haemagglutinin (HA) and poly-histidine tags, can allow for immunoblotting 
and enrichment of a probe-labelled enzyme from a cell sample to determine labelling to 
target proteins. Biotin tags can also be used to facilitate proteomic analysis of probe labelling 
within a whole-cell lysate to efficiently identify ABP targets. Biotin is particularly useful for 
proteomics since treatment of a cell sample with streptavidin/avidin will induce high-affinity 
binding of biotin to avidin and significantly reduce background labelling to non-targets.126 The 
use of fluorophores such as tetramethylrhodamine (TAMRA) and fluorescein isothiocyanate 
(FITC) can be utilised in experiments to validate probe-labelling to a specific target. For 
example, if a particular protein is being targeted by the ABP, then fluorescent labelling can 
allow for the rapid validation of probe labelling to the target protein.125 Fluorescent labelling 
also facilitates studies of labelling kinetics such as fluorescence polarisation (FP) to quantify 
the association of the fluorophore with the target protein which allows determination of 
binding affinity and rate of binding. This is also useful for inhibitor screening as it can provide 
information on inhibitor activity, as probe labelling decreases with inhibitor binding.127 
Therefore, whilst useful if a specific ABP protein target is sought out, the use of fluorescent 
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reporter tags, unlike epitope/biotin tags, provide little purpose for the identification of yet-
unknown ABP targets. 
 
1.3.3 – Activity Based Probes in Ubiquitylation 
 
E3 ABPs 
 
ABPs have been used to elucidate key findings in the activation of enzymes. Due to the multi-
step enzymatic cascade underlying the activation of its components, ABPs have shown 
particular promise within the ubiquitin-proteasome system. In particular, the first probes for 
E3 ligases were developed in 2016 and has allowed for studies on interesting pathologically-
important proteins such as the E3 ligase Parkin.128 Parkin plays a major role in mitochondrial 
homeostasis by ubiquitylating substrates such as mitofusin (Mfn)-1 and -2 which normally act 
as fusion proteins to facilitate oxidative phosphorylation within the mitochondria.129 However 
during mitochondrial damage it is vital that these substrates are degraded to prevent 
oxidative stress which would otherwise lead to neurodegeneration.130 Autosomal recessive 
mutations in Parkin are a major cause of Parkinson’s Disease, which is the second most 
common human neurodegenerative disease.131 Mutations in Parkin lead to its loss of activity 
and results in accumulation of Parkin substrates, leading to Parkinson’s Disease 
pathophysiology.130 The mechanism of Parkin activation was unclear as it is autoinhibited in 
a resting state and therefore its abundance does not correlate with substrate ubiquitylation. 
An ABP for Parkin was developed which has an activated vinylsulfide (AVS) conjugated to C-
terminus of ubiquitin acting as an electrophilic warhead for catalytic cysteine within the 
Parkin active site.128 Selectivity of the ABP to Parkin was achieved by conjugating the AVS-Ub 
warhead to the E2 enzyme UBE2L3 which acts as a substrate for Parkin. A TAMRA fluorophore 
was used as the reporter tag which allowed for probe labelling studies for Parkin (Figure 12). 
Activity-based protein profiling with the ABP showed that activation of Parkin requires its 
phosphorylation by PTEN-induced kinase 1 (PINK1) on Ser65 in response to mitochondrial 
depolarisation. Therefore the ABP has shown promise as a novel biomarker for Parkin activity, 
which is clinically useful as there is currently no test for the early diagnosis of Parkinson’s 
Disease.128 Furthermore, an ABP is a highly powerful tool for drug discovery as it allows for 
screening of drugs which modulate target activity. 
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Figure 12: Structure of ABP for Parkin. The warhead consists of Ub-AVS. The E2 enzyme 
UBE2L3 is the recognition element, which is attached to a TAMRA reporter tag. Figure taken 
from Pao et al.128 
 
DUB ABPs 
 
The development of ABPs targeting DUBs is also an area of particular interest and has led to 
many significant findings in the field. Up until recently, only thiol DUB ABPs have been 
developed. The first ABP for DUBs was designed in 2001 using ubiquitin as a recognition 
element and vinyl sulfone for the electrophilic warhead to target the catalytic cysteine in a 
range of thiol DUBs.132 Similarly, a vinyl sulfone (VS) DUB probe containing ubiquitin-aldehyde 
as the recognition element was utilised to solve the first structure of a DUB bound in complex 
with ubiquitin.133,134 These probes were also used to discover novel DUBs such as the 
proteasomal DUB USP14 and the OTU family of DUBs.135,136 ABPs have also been utilised to 
determine the effects of a stimulus on DUB activity, so as to elucidate cellular function. For 
example, in an in vitro adipogenesis model, the use of the Ub-VS probe showed an increase 
in USP7 activity, revealing its role in the regulation of adipogenesis (the production of fat cells, 
adipocytes). It was then proved that USP7 does in fact play a key role in adipogenesis through 
the deubiquitylation of the adipocyte differentiation regulator Tip60.137 Similarly, this ABP 
was employed in Salmonella-infected macrophages to look at DUB activity within the innate 
immune response. It was identified that UCHL3 activity decreased whereas proteasomal DUB 
UCHL5 activity increased which induces the secretion of the cytokine interleukin-1β (IL-
1β).136,138 
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A widely-used application of ABPs is in the screening of inhibitor selectivity. Namely, the Ub-
VS probe was used to determine selectivity during the development of the only DUB inhibitor 
to reach clinical trials, VLX1570. Assays with the ABP showed that VLX1570 selectively inhibits 
proteasomal DUBs USP14 and UCHL5, thus behaving as a proteasome inhibitor.139 
 
Although there have been many scientific advances using thiol DUB ABPs, probes for JAMM-
family DUBs have only recently been developed. Within the former, a nucleophilic thiol group 
forms an intermediate with the carbonyl group in the isopeptide bonds of ubiquitin 
conjugates. This is relatively straightforward to mimic by attaching an electrophilic warhead 
such as VS, AVS or dehydroalanine (Dha) onto ubiquitin.128,132,140 However, JAMM DUBs do 
not directly bind to Ub conjugates, the active site Zn2+ ion coordinates water to attack the 
isopeptide bond. Therefore, it has been difficult to design a probe that can mimic this 
substrate. Recently, Hameed et al. developed the first ABP for a JAMM DUB, incorporating 
ubiquitin as the recognition element and, on the C-terminus of ubiquitin, a derivative of the 
zinc chelator 8‐mercaptoquinoline (8MQ) as the warhead.141 The Ub-8MQ probe was shown 
to label an array of JAMM-family DUBs including Rpn11/Rpn8, AMSH and AMSH-LP. 
Applications of this probe within cellular and inhibitor studies have not yet been described. 
 
1.4 – Project Aims 
 
This project aimed to synthesise an activity-based probe for the Cop9 signalosome subunit 
deneddylase CSN5. The warhead consists of a zinc chelator, which binds to the Zn2+ in the 
active site JAMM domain of CSN5. Selectivity of the ABP is facilitated by the incorporation of 
NEDD8 as the recognition element. A biotin reporter tag allows for in vitro testing of probe 
labelling. 
 
Three different zinc binding groups were set out to be incorporated onto the C-terminus of 
NEDD8 to act as the warhead: hydroxamic acid, which is a commonly used zinc chelator due 
to its strong affinity for zinc binding; a precursor of the selective CSN5 small molecule inhibitor 
CSN5i-3; and imidazole, which provides the zinc chelating functionality of CSN5i-3 (Figure 13). 
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Figure 13: Warheads to be installed on the activity-based probe. 
 
As NEDD8 is the enzymatic substrate for CSN5, the full NEDD8 protein was to be used as the 
recognition element. The C-terminus of NEDD8 in particular binds to the active site of CSN5, 
therefore a 12-residue peptide of the NEDD8 C-terminus was utilised in a second probe. 
To allow for in vitro probe labelling of cell lysates, biotin was conjugated onto the N-terminus 
of the NEDD8 recognition element. 
 
 
Figure 14: Schematic of the proposed CSN5-targetting activity-based probe. Biotin is 
conjugated to the N-terminus of NEDD8 and the zinc-binding group (ZBG) to the C-terminus. 
 
Following assembly of the probe, co-immunoprecipitation assays will be performed to 
validate selective labelling of the probes to CSN5. Subsequent work can be performed to 
study the activity of CSN5, such as inhibitor screening and experiments to ascertain the 
biochemical mechanism of CSN5 activation. Rapid isopeptidase activity has prevented the 
acquirement of an X-Ray structure of the CSN5-NEDD8 complex. Therefore, labelling with the 
full-NEDD8 probe allows for the complex to be trapped in a bound state and can facilitate the 
use of X-Ray diffraction to solve a high-resolution crystal structure of the complex. Due to 
only the recent development of JAMM ABPs, these DUBs have not undergone the rigorous 
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studies of their thiol-based DUB counterparts. However, whilst untested, the ubiquitin-8MQ 
ABP does not likely target CSN5, which is selective for NEDD8. Therefore a NEDD8-based ABP 
for CSN5 can enable research into the unknown properties of, not only CSN5, but the entire 
CSN complex. This holds significant pharmacological interest due to the implications of CSN5 
overactivity and overexpression in human cancers. 
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Chapter 2 – Results and Discussion 
 
2.1 – CSN5i-3 Precursor Warhead Synthesis  
 
2.1.1 – Synthesis 
 
In the discovery of CSN5i-3, a precursor molecule was synthesised and reported in the 
literature, which was used to derive CSN5i-3. It was decided that this molecule would be used 
as a warhead in the CSN5 ABP. This molecule contains a zinc-chelating imidazole for 
attachment to the CSN5 JAMM site and has a free amine to conveniently facilitate the 
conjugation to the NEDD8 C-terminus. Schlierf et al.115 previously described the synthesis of 
the target molecule which was reproduced in this project, with alterations in the synthesis 
highlighted in this chapter. The overall synthetic route of the molecule is highlighted in 
Scheme 1. All successful reactions produced moderate to high yields. 
The synthesis begins from commercially available 4-iodoimidazole which underwent 
protection with a trityl group by an SN1 reaction to give 1 in 86% yield. This was then followed 
by Negishi coupling with an alkyl zinc bromide to give 2 in 42% yield. In parallel, Suzuki 
coupling of 3-bromo-4-methylbenzonitrile to phenylboronic acid was performed to give 3 in 
87% yield. Compound 3 then underwent bromination by a Wohl-Ziegler reaction producing 4 
in 64% yield. The Negishi product 2 and the aryl bromide nitrile 4 were conjugated together 
by SN2 and the trityl group was sequentially deprotected to give 5 in 57% yield. This would 
then further undergo cyclisation and subsequent reduction of the ketone to a hydroxide. The 
nitrile on the product can then be hydrolysed into a carboxylic acid. This carboxylic acid 
undergoes Curtius rearrangement to produce a BOC-protected amide, which can finally 
undergo deprotection to yield the final product. 
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Scheme 1: Synthetic route for the synthesis of the CSN5i-3 precursor, based on Schlierf et 
al.115 
  
 42 
2.1.2 – Trityl Protection of Iodoimidazole 
 
The first step in the synthesis consists of the protection of the 4-iodoimidazole amine by 
nucleophilic substitution (SN1) reaction to form 4-iodo-tritylimidazole (1) . This step is key in 
ensuring that coupling of the Negishi product (2) occurs on the correct nitrogen of the 
imidazole and also prevents the zinc bromide Negishi reagent from being quenched. Under 
basic conditions, the trityl chloride undergoes a kinetically slow reaction with the chloride 
acting as a leaving group to produce a stable tertiary carbocation. This is the rate limiting step 
of the SN1 reaction and the rate is increased by the stability of the carbocation. Therefore SN1 
reactions with unstable carbocations are less favourable kinetically. Furthermore, the choice 
of leaving group in the reactant is important in determining the rate of reaction. A good 
leaving group such as chloride will improve the reaction rate. In a rapid second step, following 
deprotonation of the imidazole amine by Et3N, the nitrogen anion acts as a nucleophile 
attacking the tertiary carbocation. Alternatively, the lone pair on the amine can attack the 
carbocation first and is then deprotonated by the Et3N. The reaction proceeded readily and 
provided compound 1 in an 86% yield. 
SN1 reactions typically prefer polar protic solvents, however trityl chloride is not soluble in 
these solvents. Therefore, the reaction must be performed using an aprotic solvent such as 
DMF, DCM or THF. As there are no hydrogen-bonding interactions that can occur, the 
reactivity of trityl chloride largely relies on the electron withdrawing effects of the benzyl 
groups. 
 
 
Scheme 2: Mechanism for SN1 reaction of 4-iodoimidazole and trityl chloride. 
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2.1.3 – Negishi Coupling 
 
The 4-iodo-tritylimidazole (1) underwent Negishi coupling to 4-ethoxy-4-oxobutylzinc 
bromide to form Ethyl 4-(1-trityl-1H-imidazol-4-yl)butanoate (2). Negishi couplings are 
palladium- (and less-commonly nickel-) catalysed cross-coupling reactions which couple 
organozinc reagents as nucleophiles to organohalides or sulfonate esters as electrophiles by 
forming carbon-carbon bonds. This type of coupling was discovered by Ei-ichi Negishi who 
first described it in 1977 for the coupling of asymmetrical biaryls.142 However, the reaction is 
not limited to the synthesis of biaryls. Whilst the reaction can be catalysed by either palladium 
or nickel, palladium is typically preferred as it tends to produce higher yields and has greater 
functional group tolerance. The Negishi coupling is distinct from most other palladium-
catalysed coupling reactions as it enables the coupling of sp3, sp2 and sp carbons as opposed 
to Heck reactions, for example, which only allow for sp2 coupling. Whilst Stille coupling also 
permits coupling of these carbons, its use of organostannes is highly toxic and therefore 
Negishi coupling is preferable due to its relatively low toxicity. Furthermore, unlike Suzuki and 
Stille coupling, Negishi coupling does not require a base due to the high reactivity of the 
organozinc reagent. A major stipulation of Negishi couplings is that organozinc compounds 
are air and moisture sensitive and must therefore be performed in a dry and inert 
environment to avoid reactions with water and oxygen.  
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Scheme 3: Catalytic cycle for palladium-catalysed Negishi coupling to synthesise 2 
 
In the first step of the reaction, Pd(0) undergoes oxidative addition with the 4-iodo-
tritylimidazole, oxidising the palladium to Pd(II) in the process. Whilst the exact mechanism 
of oxidative addition in Negishi couplings is not known, there are two likely possibilities for 
this step. The first is a concerted reaction and the second possible way is by an SN2-like 
reaction. Due to the steric hindrance caused by the iodoimidazole, the latter is unlikely. In this 
step, the bond between the iodine and tritylimidazole is broken and palladium is 
subsequently bound to both components. 
 
 45 
 
 
Scheme 4: Oxidative addition step of Negishi coupling. Can only progress by concerted route 
due to steric hindrance of the iodoimidazole.  
 
The second step is transmetalation, which refers to the transfer of an organic substituent 
from a more electropositive metal to a less electropositive metal. In the case of this Negishi 
coupling, the zinc in 4-ethoxy-4-oxobutylzinc bromide exchanges its organic substrate for the 
iodine in the Pd(II) complex. This results in the palladium forming a complex with both the 
tritylimidazole and 4-ethoxy-4-oxobutyl substituents and also the formation of a zinc halide 
salt. The resulting palladium complex exists in equilibrium between its cis and trans isomers, 
however only the cis form is active in the coupling.  
 
 
Scheme 5: cis/trans isomerisation of the palladium complex following transmetalation. 
 
The third step of the reaction is reductive elimination, which is the reverse of oxidative 
addition, whereby the Pd(II) eliminates the product by forming a C-C σ-bond between R and 
R’. This is a concerted process and therefore the organic substituents must be cis to each 
other. In the process, Pd(II) is reduced to regenerate catalytic Pd(0).  
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Scheme 6: Reductive elimination of the cis palladium complex by a concerted route. 
 
Compound 2 was successfully synthesised, as determined by NMR and HRMS with a moderate 
yield of 42%. Whilst it is known that Negishi couplings occur with lower yields than other 
cross-coupling reactions, the yield achieved was still considerably lower than the reaction 
published by Schlierf et al. (72%).115 The first likely reason for this is loss of product during 
purification. Furthermore, the reaction was attempted with an extended reaction time (14 h) 
however, this did not improve yield.  Additionally, it was observed by TLC that full conversion 
of the limiting reagent was not accomplished. After multiple attempts of the synthesis, it was 
realised that conversion of starting material is dependent on the dryness and inertness of the 
reaction environment. Initially the reaction was performed by purging the flask with nitrogen 
gas, which is routinely used in the lab, however under this condition only low yields of ~15-
20% were reached. Upon switching to argon gas, higher yields of up to 42% were achieved. 
This is due to argon being considerably drier and heavier than nitrogen and therefore adds a 
more robust blanket of protection on the organozinc reagent against air and moisture. This 
emphasises the necessity of stringent reaction conditions to prevent moisture and air from 
reacting with the organozinc reagent and interfering with the reaction. It can be stipulated 
that further adaptations and improved technical proficiency in the experimental setup to 
ensure that no moisture or air contamination occurs may improve the yield.  
 
2.1.4 – Suzuki Coupling 
 
Suzuki coupling of 3-bromo-4-methylbenzonitrile and phenylboronic acid to 6-methyl-[1,1’-
biphenyl]-3-carbonitrile (3) was performed. The Suzuki coupling, like the Negishi reaction, is 
a palladium-catalysed cross-coupling reaction and was first described by Akira Suzuki in 
1979.143 It is commonly used for the formation of carbon-carbon single bonds between an 
organoboron species and a halide to produce a conjugated system of alkenes, styrenes and 
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biaryls. Unlike Negishi coupling, Suzuki reactions only permit the coupling of Sp2 and Sp3 
carbons. Furthermore, Suzuki coupling requires the use of a base. Benefits of Suzuki coupling 
over Negishi include higher functional group tolerance, greater yields and the reaction is not 
air or moisture sensitive and can thus proceed in less stringent conditions. Moreover, the 
reaction is significantly less toxic for the environment than other coupling methods due to 
the use of boronic acids which are safer than organozinc or organotin reagents, for example. 
Likewise, the use of H2O as a solvent in the reaction makes it more economical and can be 
widely used with water-soluble reagents. Mechanistically, Suzuki coupling proceeds similarly 
to the previously described Negishi coupling, with the main difference being the use of base 
to produce a boronate intermediate prior to transmetalation. 
 
Scheme 7: Catalytic cycle of coupling of Suzuki coupling for the synthesis of 3. 
 
The first step involves the oxidative addition of 3-bromo-4-methylbenzonitrile to Pd(0), 
forming an organopalladium complex and oxidising Pd(0) to Pd(II) in the process. In this step, 
the carbon-bromide bond is broken and allows for both the bromide and the organic 
substituent to bind to the palladium. 
The second step is transmetalation which is mechanistically distinct from Negishi couplings. 
A base (Cs2CO3) is added which activates water to undergo a ligand exchange from the 
palladium complex, resulting in a palladium-hydroxide complex and free bromide. In parallel, 
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phenylboronic acid also reacts with Cs2CO3 to form a boronate complex. The hydroxide on 
the palladium complex is exchanged for the phenyl group on the boronate complex, resulting 
in a palladium complex with both organic substituents (Scheme 7).144 
 
As in Negishi coupling, transmetalation results in cis/trans isomerisation of the palladium 
complex, with only the cis conformation able to undergo reductive elimination. In this step, 
the organic substituents form a carbon-carbon bond and are released from the palladium 
complex. Pd(II) is reduced to Pd(0) in the process and thus the catalyst is regenerated.  
 
The product 3 was successfully synthesised with a yield of 87%, as determined by NMR and 
HRMS. As expected, the yield of this coupling reaction was greater than that of the Negishi 
coupling. This is likely due to the lack of need for rigorous reaction conditions. It was 
hypothesised that an excess of phenylboronic acid is unnecessary for the reaction to proceed, 
and was thus lowered. However, it was found that the reaction does not proceed without an 
excess of boronic acid. 
 
2.1.5 – Wohl-Ziegler Reaction 
 
Bromination of the methyl group on 3 was accomplished by Wohl-Ziegler substitution to 
result in 6-bromomethyl-[1,1’-biphenyl]-3-carbonitrile (4). Wohl-Ziegler substitution refers to 
the bromination of an allylic carbon using N-bromosuccinamide (NBS) and a radical initiator. 
The reaction was first discovered in 1919 by Alfred Wohl145 with the use of N-
bromoacetamide but was later modified in 1942 by Karl Ziegler146 to include NBS after 
studying its value in the reaction. 
HBr is usually present in trace amounts with NBS. Under heat, NBS reacts with HBr to produce 
Br2 and succinimide. With the use of the radical initiator AIBN, an initiation reaction occurs 
whereby Br2 undergoes homolytic cleavage to produce bromine radicals. A free bromine 
radical then abstracts a hydrogen from the methyl group of compound 3, resulting in a radical 
on the allylic carbon and the reformation of HBr. This HBr is recycled and reacts with NBS to 
further produce Br2 to repeat the process. The second free Br radical reacts with the allylic 
carbon radical, resulting in bromination. Due to the formation of HBr in the previous step, the 
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reaction is repeated until the limiting reagent 3 or NBS are depleted or upon quenching the 
reaction with H2O.  
 
 
Scheme 8: Mechanism of Wohl-Ziegler bromination using NBS for the synthesis of 4. 
  
The use of NBS allows for the Br2 to be kept at low concentrations during the reaction. This is 
important as the desired substitution reaction is competing with an addition reaction. High 
amounts of Br2 favours addition reactions with bromine to the phenyl group. Whilst phenyl 
groups are typically resistant to addition reaction, the presence of heat and AIBN can drive 
this forward and result in the formation of an undesired product. Therefore, by keeping the 
amount of Br2 low, the use of NBS favours the substitution reaction. 
 
Typically, a consideration for allylic radical initiation reactions is that the allyl radical is 
resonance stabilised and therefore the substitution can occur on the undesired carbon. 
However, as the alkyl used is bound to a phenyl group, the aromaticity of the ring prevents 
substitution at the undesired carbon atoms.  
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The reaction is performed in carbon tetrachloride (CCl4) which limits the solubility of NBS and 
therefore the amount of Br2 generated is kept to a minimum. Reaction completion is also 
indicated by the precipitation of the resulting succinimide. A major issue with the use of CCl4 
as a solvent is its high toxicity and ozone-depleting causing environmental concerns. Going 
forward, environmentally safe reagents should be explored to limit the amount of hazardous 
waste generated. Such a solvent includes trifluorotoluene whose use has been reported in a 
similar reaction.147 
Initial reactions were attempted by stirring at reflux for 20h, however it was observed by TLC 
that a large amount of the limiting reagent 3 had not been consumed. In an endeavour to 
increase conversion, it was hoped that an increase in reaction pressure would improve 
conversion to product. The reaction was further performed under microwave conditions with 
heating for 2h. It was found by TLC that the use of microwave-assisted synthesis greatly 
improved consumption of the starting material with an observed yield of 64% of the product 
4. This moderate yield can be attributed to product loss during purification.  
 
2.1.6 – Conjugation of Negishi and Wohl-Ziegler Products 
 
The products 2 and 4 underwent coupling and subsequent deprotection in a one pot synthesis 
reaction, producing dialkyl imidazole (5). At room temperature, the imidazole nitrogen on 2 
acted as a nucleophile and attacks the bromo-methyl group on 4 in an SN2 reaction. Following 
this conjugation, acetonitrile was removed and methanol was added to the reaction and the 
reaction mixture was then refluxed. The trityl-imidazole bond is broken and the electrons in 
the imidazole ring are transferred onto the nitrogen cation, resulting in product 5. The 
carbocation formed on the trityl group is attacked by methanol forming a stable methoxy 
substituted trityl side product. Because acetonitrile does not possess an acidic hydrogen, it 
can add to the trityl group but the adduct is unstable and so can reattach to the imidazole in 
a reverse reaction.  
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Scheme 9: Mechanism of SN2 reaction and subsequent deprotection of trityl group. 
 
Despite difficulties in the purification of the product whereby the polarities of the product 
and an impurity were similar and thus were difficult to separate. Compound 5 was isolated in 
a yield of 57%.  
 
As SN2 reactions favour polar aprotic solvents, acetonitrile was used in the reaction for this 
step. However, the yield may be improved with the use of anhydrous acetonitrile, ensuring 
that no water hinders the progression of the reaction. Furthermore, the reaction was only 
performed at a small scale with only 50 mg (0.18 mmol) of limiting reagent. Therefore scaling 
up the reaction would likely make the purification less technically challenging, resulting in 
larger yields. 
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2.1.7 – Conclusion 
 
The synthesis of a precursor molecule to the CSN5 inhibitor CSN5i-3 was attempted by the 
route highlighted in chapter 2.1.1 (scheme 1). Of the proposed synthetic route, five steps 
were successfully accomplished to produce compound 5 at an overall yield of 11.5%. Due to 
time constraints, the synthesis of the target molecule was not completed, with a further five 
steps remaining. As this molecule was intended for use as a warhead in the CSN5 ABP, 
alternative zinc binding domains were explored and the overall design of the probe was 
modified accordingly. This is discussed in detail in chapter 2.2.  
 
2.2 – NEDD8 Synthesis 
2.2.1 – Computational Design of NEDD8 Synthesis 
 
Molecular Docking 
 
As mentioned in chapter 1.3.2, the recognition element needs to be designed in a way such 
that it does not disrupt the binding of the warhead to the target enzyme at its catalytic site. 
The full NEDD8 protein is the native substrate for CSN5 and thus readily occupies its binding 
site. Whilst this will unlikely interfere with the binding of a small warhead such as hydroxamic 
acid or imidazole, the relatively large size of NEDD8 will likely cause hindrance in the binding 
of a larger warhead such as the CSN5i-3 precursor to the catalytic Zn2+ atom in the CSN5 active 
site. Therefore, in designing the synthesis of NEDD8 for conjugation to the CSN5i-3 precursor, 
the size of the warhead must be taken into account and the sequence of NEDD8 must be 
truncated to facilitate optimal binding of the probe into the CSN5 catalytic site. Truncation of 
the NEDD8 sequence must occur at the C-terminus as this is the region of the protein which 
binds onto the CSN5 active site. Based on this, truncation at this end allows the CSN5i-3 
precursor warhead to act as a surrogate for the deleted C-terminal NEDD8 residues and thus 
facilitate binding onto the CSN5 active site. In order to determine the required extent of 
truncation, molecular docking was performed of both the C-terminus of NEDD8 (residues 73-
76) and the CSN5i-3 precursor warhead (Figure 15). The CSN5i-3 precursor was tert-
butoxycarbonyl (BOC)-protected to prevent interference of the free amine in the docking and 
thus generating false-positive scores. 
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Figure 15: Ligands used for docking onto CSN5. (A) C-terminal residues 73-76 of NEDD8 
(LRGG). (B) CSN5i-3 precursor with BOC protection of its free amine. 
 
The generated ligands were individually docked onto a model of active CSN5 (PDB: 5JOG) on 
the Zn2+ residue in the JAMM domain. The docking results were scored by GlideScore2 and 
models showing the strongest docking (highest scoring) of the ligands to CSN5 were selected. 
The docked 3D models were subsequently analysed to determine how the ligands bind to and 
interact with CSN5. This was further determined by generation of a 2D ligand interaction plot, 
showing which atoms of the ligand interact with CSN5 residues (Figure 16).  
 
The interactions of CSN5 with the C-terminal peptide and the CSN5i-3 precursor were 
compared to look for any correlations in their binding. It can be seen in Figure 16 that the C-
terminal Gly76 of NEDD8 interacts with the catalytic Zn2+ atom of the CSN5 JAMM domain, as 
expected. Likewise, the imidazole of the CSN5i-3 precursor also interacts with the catalytic 
Zn2+ atom, showing that its predicted coordination to zinc was successful in the docking. 
Furthermore, it was observed that the amide bond of the CSN5i-3 precursor binds to Thr154 
on CSN5 by hydrogen bonding, mimicking the interaction of the Arg74-Leu73 amide bond of 
the NEDD8 C-terminus (Figure 16). It was concluded that the CSN5i-3 precursor acts as a 
surrogate for residues 74-76 of the NEDD8 C-terminus, and so a probe of NEDD8 incorporating 
this warhead must have a truncation of 3 residues at the C-terminus to produce a 73 residue 
protein. Ideally a model would be created with the warhead conjugated to Leu73 of the 
NEDD8 protein, however software limitations prevented docking with such a ligand. 
Alternatively, a model of this probe was generated with the warhead conjugated onto a 
leucine residue acetylated at its free amine to prevent interference in the docking (Figure 17). 
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This probe was used as a ligand for docking onto the active CSN5 model, and the binding 
interactions were analysed. It was observed that binding occurs as expected, with the 
warhead mimicking the C-terminal residues 74-76 (Figure 18). 
In conclusion, assembly of an ABP utilising NEDD8 and the CSN5i-3 precursor requires 
synthesis of NEDD8 (1-73) instead of the full protein (1-76) to allow for binding to the CSN5 
active site. 
 
 
Figure 16: 3D models and 2D ligand interaction plots of ligands docked onto a model of active 
CSN5. Hydrogen bonding is indicated by pink lines. (A) Docking of CSN5i-3 precursor showing 
hydrogen bonding between amine and Thr154 on CSN5. (B) Docking of NEDD8 C-terminal 
peptide LRGG (73-76) revealed hydrogen bonding between the Leu73-Arg74 amide bond of 
the ligand and Thr154 on CSN5, showing a correlation between the docked models.   
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Figure 17: CSN5i-3 precursor warhead conjugated onto an acetylated leucine residue. 
 
 
Figure 18: 3D model and 2D ligand interaction diagram of the CSN5i-3 precursor conjugated 
to leucine, docked onto a model of active CSN5. Hydrogen bonding is indicated by pink lines. 
The imidazole of the ligand coordinates zinc and, at the same time, the amide bond between 
the small molecule and leucine forms a hydrogen bond with Thr154.   
 
Structure Prediction 
 
To predict any issues that may occur during the synthesis of NEDD8, the sequence was 
submitted to the protein structure prediction server I-TASSER. This service utilises the PDB to 
look for structural templates and uses these in iterative fragment assembly simulations to 
generate atomic models from an amino acid sequence.148 This was performed to check if the 
service could correctly predict the secondary structures of NEDD8 and highlight any problem 
areas which could occur during protein synthesis. If the service incorrectly predicted the 
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secondary structure, it may be an indication of potential issues that may arise during synthesis 
and would allow for adequate planning of the synthesis design to address these problems. 
This predicted structure was compared to the published crystal structure of NEDD8. The 
server was able to accurately predict the secondary structures, and no major deviations from 
the published structure were observed. Therefore, it was deemed unlikely that issues in 
secondary structure formation would arise during NEDD8 synthesis. 
 
Figure 19: (A) NEDD8 structure (left) [PDB: 1NDD] and output model of structural NEDD8 
prediction by I-TASSER (right). (B) Superimposition of models to display alignment of 
secondary structures. 
 
 
2.2.2 – Solid-Phase Peptide Synthesis of NEDD8 Protein 
 
In the first instance, synthesis of the full NEDD8 protein was attempted. The chemical 
synthesis of NEDD8 has not been reported but the synthesis of ubiquitin has been described 
by Oualid et al.149 This provided precedence for the total synthesis of NEDD8 using a solid 
phase approach. 
 
 A major benefit of using the full protein as a recognition element in the ABP is that it acts as 
a complete native substrate for CSN5, and is thus able to replicate all of the protein-protein 
interactions between CSN5 and NEDD8. Furthermore, successful labelling of active CSN5 with 
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this ABP will produce a stable NEDD8-CSN5 complex which could be used to obtain the first 
X-Ray crystal structure of this complex. Previously, it has not been possible to obtain an X-Ray 
structure due to the isopeptidase activity of CSN5 rapidly cleaving the isopeptide bond 
between the proteins. Because ABP labelling is irreversible, a stably-bound CSN5-NEDD8 
complex will be produced which could allow for extensive structural analysis by 
crystallography. 
 
Due to the incomplete synthesis of the CSN5i-3 precursor, as described in Chapter 2.1, 
development of the ABPs were proceeded by utilising hydroxamic acid and imidazole as the 
respective zinc binding groups (Figure 13). As these warheads are significantly less bulky than 
the CSN5i-3 precursor, it does not require attachment to a truncated NEDD8 protein and must 
instead be conjugated to the full NEDD8 protein (1-76). It was therefore unnecessary to 
synthesise a truncated NEDD8 protein and synthesis of the full NEDD8 protein (1-76) was 
instead proceeded by Fmoc-based solid-phase peptide synthesis (SPPS). 
 
Whilst computational prediction (Chapter 2.2.1) showed that there was unlikely to be any 
major issues in secondary structure formation, the large 5-stranded β-sheet was still likely to 
be a major problem area in the synthesis. β-structure formation is known to cause lowered 
solubility and solvation and, in turn, aggregation of a peptide during synthesis150. Due to the 
relatively large sequence to be synthesised, there was a high possibility of protein aggregation 
during the formation of this β-sheet. Pseudoproline dipeptides were utilised in an attempt to 
minimise the risk of forming these secondary structures, and thus avoid aggregation during 
the synthesis.150 Pseudoprolines consist of serine- or threonine-derived oxazolidines or 
cysteine-derived thiazolodines which form heterocycles akin to proline. This creates a kink in 
the peptide and prevents β-sheet formation and aggregation during synthesis.150 Following 
complete synthesis of the protein, pseudoprolines can be cleaved with TFA to generate the 
intended peptide sequence and allow for protein folding (Scheme 10).150,151 Pseudoproline 
dipeptide building blocks were inserted in the NEDD8 sequence where serine or threonine 
residues were present. The building blocks were placed at regions where they are spaced 
apart by at least 5 residues to allow for optimum formation of kinks in the protein backbone. 
Proline residues in the sequence are also taken into account and thus pseudoprolines do not 
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need to be incorporated in a region of the sequence where there is a native proline (Figure 
20). 
 
Scheme 10: Gly-Ser pseudoproline dipeptide heterocycle can undergo cleavage by TFA to 
result in native peptide sequence.  
 
Figure 20: NEDD8 sequence with pseudoproline dipeptide building block insertions 
highlighted in yellow. Native prolines in the sequence are highlighted in green. The building 
blocks were incorporated across the whole sequence and spaced by at least 5 residues. 
 
Synthesis of the protein was performed on a 0.05mmol scale using NovaSyn tentagel 4-
carboxytrityl (TGT) resin pre-loaded with Fmoc-glycine at 0.21mmol/g loading. This resin 
consists of polystyrene beads conjugated to a polyethylene glycol (PEG) linker, and 
subsequently an amide-carboxytrityl linker where Fmoc-Gly is coupled. The PEG linker 
increases the polarity and swelling ability of the resin, making it useful for the synthesis of 
long peptides or proteins as it reduces the risk of aggregation.152,153 NovaSyn TGT also has a 
low-loading capacity which minimises entanglement of peptide chains during elongation and 
is therefore preferred for long peptide synthesis as it reduces the risk of issues such as 
aggregation.154,155 This resin generates a peptide with carboxyl functionalisation at the C-
terminus. Moreover, the resin is highly acid labile and can therefore be cleaved under weak 
acidic conditions. This was necessary to avoid removal of protecting groups on the peptide to 
allow for selective modifications of the C-terminus. 
 
To determine the optimum conditions for protein synthesis, an initial microwave-assisted 
SPPS of the NEDD8 C-terminal peptide LRGG (residues 73-76) was attempted. At a 0.05mmol 
scale, the Fmoc-Gly NovaSyn TGT resin was swollen in DCM before deprotection of the Fmoc 
in 20% piperidine in DMF. Coupling of the first residue (glycine) was performed using HCTU 
and DIEA in DMF at 70°C for 5 minutes under microwave irradiation. Following coupling of 
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the first residue, the peptide was washed with DMF and the deprotection/coupling process 
was repeated for each residue in the elongation of the peptide to result in Fmoc-LRGG 
(Scheme 11). This was cleaved from the resin with 95% TFA and analysed using LC-MS. 
However, no peptide mass was observed. 
 
 
Scheme 11: Scheme of unsuccessful microwave-assisted SPPS of the NEDD8 C-terminal 
peptide LRGG. 
 
To determine if the unsuccessful synthesis was due to temperature, the synthesis was 
repeated without microwave assistance and the coupling was instead performed at room 
temperature for 1 hour (Scheme 12). It was confirmed by LC-MS that the synthesis was 
successful under these conditions. Therefore, the synthesis of the NEDD C-terminus was 
possible at room temperature but not under microwave conditions. It was suspected that 
diketopiperazine formation of the di-glycine residues was occurring, resulting in low peptide 
yield. Here, the free amine of the distal glycine, following Fmoc deprotection, attacks the 
carbonyl group linking the proximal glycine to the resin. This results in cyclisation of the di-
glycine peptide and its detachment from the resin (Scheme 13). To confirm this, a di-glycine 
dipeptide was synthesised on Fmoc-Gly NovaSyn TGT resin using HCTU/DIEA at 70°C under 
microwave for 5 minutes. Following deprotection of the distal glycine, the piperidine/DMF 
eluent was collected without prior resin cleavage and analysed by ESI high resolution mass 
spectrometry. The mass of cyclic di-glycine was observed (expected mass = 113 Da, observed 
mass = 114 Da), confirming diketopiperazine formation. To further confirm that no peptide 
was bound to the resin, cleavage with 95% TFA was performed prior to analysis and no 
peptide mass was observed. Therefore, microwave-assisted SPPS of the di-glycine residues 
catalyses diketopiperazine formation, which does not occur at room temperature. This is 
highly unusual as the bulkiness of the NovaSyn TGT resin would be expected to provide steric 
hindrance to the free amine nucleophile and prevent cyclisation.  
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Scheme 12: Scheme of SPPS of NEDD8 C-terminus at room temperature 
 
 
Scheme 13: Mechanism of cyclic di-glycine (diketopiperazine) formation under microwave 
conditions. 
 
Upon this realisation, SPPS of the full NEDD8 protein was attempted by first synthesising the 
C-terminal region at room temperature before proceeding to elongate the peptide by 
microwave-assisted synthesis at 70°C. This approach avoids the issue of di-glycine cyclisation 
whilst also avoiding complete protein synthesis at room temperature, which would be a 
highly time-consuming process. 
 
The synthesis was performed on a 0.05 mmol scale, again using Fmoc-Gly NovaSyn TGT resin. 
The glycine, arginine and leucine residues were sequentially coupled onto deprotected 
glycine-loaded resin using HCTU/DIEA in DMF at room temperature for 1 hour. Following the 
synthesis of LRGG at room temperature, the peptide was elongated using HCTU/DIEA 
coupling in DMF at 70°C under microwave for 5 minutes (Scheme 14). Due to the large β-
sheet secondary structure of the protein there was a risk of decreased solvation of the 
growing peptide chain and thus inefficient amino acid coupling later in the synthesis. 
Therefore, after coupling of 32 residues (NEDD8 45-76), the subsequent 44 residues (NEDD8 
1-44) underwent double coupling to increase the probability of successful amino acid 
coupling. 
 
 61 
 
 
Scheme 14: Scheme of attempted synthesis of the full NEDD8 sequence. Coupling of the initial 
3 residues performed at room temperature to avoid diketopiperazine formation followed by 
microwave-assisted synthesis at 70°C for elongation of the peptide. 
 
To monitor the synthesis of the protein, a test cleave was performed at intervals during the 
synthesis whereby a small amount of resin was collected and the peptide cleaved with 95% 
TFA for analysis by LC-MS and HPLC (Figure 21). 
 
 
Figure 21: NEDD8 sequence with sites of test cleavage highlighted in cyan and numbered 
chronologically. 
  
The first test cleave was performed after coupling of 24 residues and was deemed successful 
with the correct mass observed on LC-MS (expected mass = 2819 Da, observed mass = 2820 
Da) (Figure 22) and a significant analytical HPLC peak of the crude product was seen. 
The second test cleave was carried out after coupling of 51 residues. Whilst the correct mass 
was observed on LC-MS (expected = 5835 Da, observed = 5835 Da) the analytical HPLC trace 
only showed a very small product peak, suggesting that only trace amounts of the product 
was synthesised. 
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Figure 22: LC-MS of NEDD8 residues 52-76 + Fmoc. m/z expected [M/3] = 940, found 940. m/z 
expected [M/2] = 1410, found 1410. 
 
The final test cleave was performed upon completion of the protein synthesis. The mass of 
the desired product was not observed on LC-MS (expected = 8782 Da) and thus the synthesis 
was unsuccessful. However, a clear peak was observed on the analytical HPLC and, upon 
analysis on LC-MS, the mass appeared to be of 7224 Da. This mass does not correspond with 
the product nor any amino acid deletions from the N-terminus of the sequence. Therefore, 
the observed product was unable to be identified. A likely explanation for the failed synthesis 
is aggregation of the protein upon elongation. Whilst not unexpected given the large β-sheet 
component, the risk of aggregation should have been minimised with the use of low-loading 
resin and the insertion of pseudoprolines, as in the reported synthesis of ubiquitin.149 
Potential next steps for synthesis of the protein may consist of increasing the amino acid 
concentration and coupling time to allow greater chance of coupling, or by conducting the 
entire synthesis at room temperature. An additional strategy to prevent aggregation is by the 
incorporation of Hmb or Dmb amino acids.155 These act similarly to pseudoprolines whereby 
the backbone amide bond of the residue is protected by a cyclic ring which creates a kink in 
the sequence and prevents secondary structure formation until cleaved. However, whilst 
pseudoproline dipeptides can only be placed where there is a serine or threonine residue in 
the sequence, Hmb/Dmb amino acids can be inserted at any point in the sequence. Therefore 
incorporation of the amino acids would likely alleviate the risk of protein aggregation.  
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2.2.3 – Solid-Phase Peptide Synthesis of NEDD8 C-terminal Peptide 
 
The C-terminus of NEDD8 is the site of isopeptidase activity of CSN5, and as such is a major 
protein-protein interaction site within the complex. Therefore, a C-terminal peptide of NEDD8 
was deemed an appropriate recognition element in the development of a CSN5 ABP. This 
retains the ability of the probe warhead to interact directly with the catalytic zinc atom of the 
CSN5 JAMM site whilst still acting as a substrate of CSN5, thereby enabling efficient probe 
binding. Previous studies on ubiquitin and Ubl C-terminal ABPs with vinyl sulfone warheads 
have demonstrated that a 12-mer C-terminal peptide is sufficient to achieve probe labelling 
to DUBs and Ubl-specific proteases.156 This approach was applied here with the synthesis of 
a 12-mer from the C-terminus of NEDD8 (SVLHLVLALRGG). 
 
As the sequence to be synthesised was relatively short, and had little risk of aggregation, a 
low-loading resin such as NovaSyn TGT was not necessary for this synthesis. Alternatively, a 
less costly, widely available, high-loading resin was used. The synthesis was carried out on a 
0.3 mmol scale using 2-chlorotrityl resin preloaded with glycine at a loading of 0.78 mmol/g. 
Similarly to NovaSyn TGT resin, this resin is highly acid labile and also produces carboxyl 
functionalisation of the C-terminus. The resin was swollen with DCM and the residues were 
sequentially coupled on using HCTU and DIEA in DMF at room temperature for 1 hour. Fmoc 
deprotection was performed using 20% piperidine in DMF.  
 
As biotin is a highly versatile label which allows for a diverse array of probe-labelling assays 
such as proteomics and immunoprecipitation, it was decided that biotin would be used as the 
reporter tag in the ABP. Following synthesis of the peptide, the N-terminal serine underwent 
Fmoc deprotection before coupling of D-biotin using HCTU and DIEA in DMF for 1 hour. A test 
cleave of the biotinylated peptide was performed and analysed by ESI high resolution mass 
spectrometry (expected mass = 1460 Da, observed = 1461 Da) and analytical HPLC. The HPLC 
chromatogram showed a large significant peak, therefore the peptide synthesis and 
subsequent biotinylation was deemed successful. 
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Since the warhead was to be conjugated onto the C-terminus of the peptide, it needed to be 
ensured that, where available, the residues on the peptide remained protected with Pbf, Trt 
and tBu groups on serine, histidine and arginine, respectively, so that any modifications 
occurred only at the C-terminus and that these residues did not interfere with the conjugation 
reactions, such as by cyclisation. Cleavage of the peptide from resin with 95% TFA also 
deprotects the peptide and removes the protecting groups throughout the chain. Therefore, 
the acid labile 2-chlorotrityl resin was used in the synthesis as it allows for cleavage of the 
peptide in low concentrations of TFA (1% TFA in DCM) whilst still ensuring that the protecting 
groups are not removed (Scheme 15). 
 
Scheme 15: Synthesis of fully-protected biotinylated NEDD8 C-terminal peptide using H-Gly-
2-ClTrt resin. 
 
2.2.4 – Conjugation of Hydroxylamine to NEDD8 C-terminal Peptide 
 
Having successfully synthesised the biotinylated NEDD8 C-terminal 12-mer peptide with 
protecting groups on arginine, histidine and serine residues, the C-terminal glycine residue 
underwent modification to yield a hydroxamic acid. This is a zinc binding group for use as a 
warhead in the ABP to target the catalytic JAMM site of CSN5. 
 
The crude protected biotinylated peptide was dissolved in DMF before the coupling of O-tert-
butyl hydroxyl amine hydrochloride using DCC and DMAP. Following the reaction, the peptide 
was treated with 95% TFA to cleave the protecting groups (Scheme 16). When analysed with 
LC-MS the mass of the product was not seen (expected mass = 1476 Da, observed = 1461 Da) 
and the analytical HPLC chromatogram shows a significant peak. The observed mass of 1461 
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Da correlates to that of the unprotected biotinylated peptide. Therefore the conjugation 
reaction was unsuccessful and the peptide remained unmodified. 
 
 
Scheme 16: Conjugation of hydroxyl amine to biotinylated NEDD8 C-terminal peptide. 
 
The hydrophobicity of the peptide caused issues in this reaction, as attempting to dissolve the 
peptide in DMF resulted in a thick jelly-like solid. This created a significant problem as the 
peptide needed to be fully dissolved in the solvent before any further reactions can occur. A 
relatively large volume of DMF was required for the peptide to dissolve, resulting in a highly 
diluted solution. It is therefore likely that the reaction concentration was too low and thus 
did not proceed. The addition of a greater concentration of O-tert-butyl hydroxyl amine 
hydrochloride, DCC and DMAP may improve the reaction and allow it to progress. To improve 
the solubility of the peptide, the sequence could be elongated to include more polar residues. 
However, the C-terminal end of NEDD8 is largely non-polar and must be extended 
significantly before generating a soluble peptide. Alternatively, a polar peptide sequence, for 
example tetra-arginine (RRRR), can be included on the N-terminus to improve solubility 
without the need of synthesising a large NEDD8 peptide. 
 
2.2.5 – Conjugation of Imidazole to NEDD8 C-terminal Peptide 
 
In a parallel approach, the biotinylated NEDD8 12-mer C-terminal peptide underwent 
conjugation of imidazole to the C-terminus. Imidazole behaves as the zinc binding group in 
the inhibitor CSN5i-3 and so was selected as a warhead within the CSN5 ABP. Stability studies 
of N-acylimidazole have shown that this system remains stable under acidic conditions.157 
Therefore there was not a risk of the imidazole group being removed under the TFA 
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conditions used for peptide cleavage. The peptide was dissolved in DMF and reacted with 
carbonyldiimidazole (CDI) and Et3N at room temperature. Following the reaction, the 
protecting groups on the peptide were cleaved using 95% TFA (Scheme 17). The product was 
subsequently analysed by LC-MS, however the correct mass was not observed (expected mass 
= 1512, observed mass = 1516). A significant peak corresponding to the observed mass was 
seen on the analytical HPLC chromatogram. With an additional mass of 4 Da it is evident that 
the desired product was not formed, however it is unclear what the observed product of the 
reaction is. As in chapter 2.2.4, there was difficulty in dissolving the peptide in DMF as it 
solidified into a jelly-like substance. A large volume of DMF was required to dissolve the 
peptide and thus the reaction concentration would have again been lowered. In the first 
instance, the concentration of the reaction would be increased in an endeavour to drive the 
desired reaction forward. 
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Scheme 17: Conjugation of imidazole to the C-terminus of the biotinylated NEDD8 12-mer C-
terminal peptide. 
 
The mechanism of the conjugation reaction is highlighted in Scheme 18. The CDI first 
deprotonates the C-terminal hydroxyl group of the peptide. The oxyanion then attacks the 
carbonyl group of CDI and releases free imidazole. Et3N deprotonates the free imidazole 
which acts as a nucleophile to attack the proximal carbonyl group on the peptide C-terminus. 
The distal carbonyl group is hindered by the attached imidazole and thus nucleophilic addition 
does not occur there. Upon addition by imidazole, the bond between the carbonyl group and 
oxygen is broken, yielding the product. 
 
Scheme 18: Mechanism of imidazole conjugation to the biotinylated peptide C-terminus using 
carbonyldiimidazole and Et3N.  
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Chapter 3 – Conclusions 
 
In an aim to investigate the biochemical mechanisms which modulate the activity of the COP9 
Signalosome (CSN), this project endeavoured to generate an activity-based probe (ABP) 
specific for the catalytic subunit CSN5. In the first instance, the synthesis of a precursor 
molecule of the potent small molecule inhibitor CSN5i-3 was attempted. This molecule was 
to be used as a zinc-binding reactive group attached to the C-terminus of NEDD8, which acts 
as the recognition element in the ABP. By means of molecular docking, it was determined that 
NEDD8 must be truncated to 73 residues to facilitate docking of the ABP to the CSN5 active 
site. The synthesis route was derived from the published synthesis of CSN5i-3 by Schlierf et 
al.115 and was followed closely. Due to time constraints and challenges arising during the 
synthesis, namely with optimising the organometallic couplings and subsequent purifications, 
the desired final product was not achieved. 
 
Due to these time limitations, priority was shifted to the generation of ABPs utilising 
alternative warheads for binding onto the catalytic Zn2+ residue of CSN5. These warheads 
included hydroxamic acid, a widely used zinc-binding group, and imidazole, which acted as 
the zinc-binding group in CSN5i-3. Two different NEDD8-based recognition elements were 
proposed in the generation of ABPs with these warheads, the first of which was the full NEDD8 
protein. Synthesis of NEDD8 (1-76) was attempted using an Fmoc-based solid-phase 
approach, however the desired product was not successfully formed. Test cleaves during the 
synthesis allowed for the successful characterisation of the peptide at 24 residues (Asp52). 
However, after the synthesis of 51 residues, a second test cleave showed that the product 
was only produced in trace amounts, as determined by analytical HPLC. Upon completion of 
the synthesis protocol, the desired product mass was not observed. Modifications in the 
synthetic approach such as inclusion of DMB dipeptides to prevent protein aggregation may 
improve the synthesis and should be explored as a next step. The second recognition element 
synthesised for these ABPs was a 12-mer C-terminal peptide of NEDD8 consisting of residues 
65-76. This peptide was successfully synthesised by an Fmoc-based solid-phase approach. 
Biotin was coupled onto the N-terminus of the peptide for use as a versatile recognition 
element for subsequent biological assays. 
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Conjugation of the imidazole and hydroxamic acid warheads to the NEDD8 12-mer peptide C-
terminus was attempted, however in both instances the reaction was unsuccessful. A major 
issue with these reactions was the hydrophobicity of the 12-mer peptide preventing sufficient 
mixing with the reagents and thus likely hindering the reaction. In the first instance, the 
solubility of the peptide must be improved before conjugation to these warheads can occur 
to produce the desired ABPs. 
 
Following the generation of these probes, they can be used within in vitro assays to assess 
labelling to CSN5. If probe labelling proves successful, the ABP can be utilised within 
biochemical studies to monitor CSN5 activity within various conditions to determine how it is 
altered. This is a highly powerful approach to elucidate the unknown properties of the enzyme 
CSN5 and, by association, the full CSN complex and its role within the pathogenesis of human 
cancer and cardiovascular diseases. 
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Chapter 4 – Experimental 
 
3.1 – Organic Synthesis 
 
3.1.1 – General Information 
 
All reagents were purchased from commercial sources and used without further purification. 
Anhydrous THF was obtained by passage through a PureSolv™ solvent purification system and 
stored with molecular sieves under nitrogen. Reactions were performed using round 
bottomed flasks on Radleys Pro hotplates. All glassware was oven dried and cooled in a 
desiccator before use. Microwave-assisted synthesis was performed in a CEM® Discover 
microwave reactor using a 35 mL reactor vial. All flash chromatography was performed using 
a Biotage® Isolera™ One automated flash column chromatography system using Biotage® 
SNAP KP-Sil normal phase pre-packed silica columns. Solvent evaporation was performed 
under reduced pressure on a Heidolph rotary evaporator. All reactions were monitored using 
Thin Layer Chromatography (TLC). TLC was also used to determine the optimal solvent system 
for flash chromatography. This was carried out using aluminium plates precoated with silica 
gel (0.25 mm, 60 Å pore-size) impregnated with a 254 nm fluorescent indicator. Visualization 
of TLC was performed using UV light at a wavelength of 254 nm. Proton Nuclear Magnetic 
Resonance spectroscopy (1H NMR) was performed on an AVANCE III 400 Bruker (400 MHz) 
system. Proton chemical shifts are expressed in parts per million (ppm, δ scale) and are 
referenced to the appropriate deuterated solvent signal (CDCl3 δ = 7.26 ppm and DMSO-d6 δ 
= 2.50 ppm). Coupling constants (J) are quoted in Hz. Peak patterns are described as singlet 
(s), doublet (d), triplet (t), quartet (q) and multiplet (m). Carbon Nuclear Magnetic Resonance 
spectroscopy (13C NMR) was performed on an AVANCE III 400 Bruker (101 MHz) system. 
Chemical shifts are reported in ppm referenced to residual protium in the deuterated solvent 
(CDCl3 δ = 77.0 ppm and DMSO-d6 δ = 39.5 ppm). High-resolution mass spectrometry (HRMS) 
was performed on a Bruker microTOF-Q II (ESI+). 
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3.1.2 – 4-iodo-1-trityl-1H-imidazole (1) 
 
To a solution of 4-iodoimidazole (500 mg, 2.6 mmol) in DMF (10 mL) was added trityl chloride 
(800 mg, 2.9 mmol) and Et3N (0.429 mL, 3.12 mmol). This was stirred at room temperature 
for 24 h before being poured into water and filtered. The filtrate was dried in vacuo and the 
crude residue was purified by flash chromatography, eluting at a gradient of 10-50% EtOAc in 
petroleum ether. The eluent was concentrated in vacuo to afford 1 as a white powder at 710 
mg (86%).  
RF = 0.5 (EtOAc/petroleum ether 2:9). 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.30 (m, 10H), 7.15 
– 7.08 (m, 6H), 6.91 (d, J = 1.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 142.0, 140.7, 129.9, 128.5, 
128.3, 127.1. HRMS: m/z expected [M+Na]+ = 459.0334 found 459.0334. Characterisation 
data is in alignment with the literature.158 
 
3.1.3 – Ethyl 4-(1-trityl-1H-imidazol-4-yl)butanoate (2) 
 
To a solution of 1 (1.0 g, 2.3 mmol) in anhydrous THF (5 mL) was added PdCl2(dppf)·DCM 
under an argon atmosphere and cooled to 0 °C. A solution of 4-ethoxy-4-oxobutylzinc 
bromide (6.9 mL, 3.45 mmol) was added to the reaction mixture dropwise. The reaction was 
then heated to 70 °C and stirred for 3 h. The reaction was cooled to room temperature and 
diluted with EtOAc before filtering through celite. The filtrate was poured into saturated 
NaHCO3 solution and extracted with EtOAc (3 X). The organic layers were combined, washed 
with brine and dried by passing through a hydrophobic frit before being concentrated in 
vacuo. The crude residue was purified by flash chromatography, eluting at a gradient of 0-
100% EtOAc in hexanes. The eluent was concentrated in vacuo to afford a brown oil at 608 
mg (42%).  
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RF = 0.45 (EtOAc/hexanes 2:9). 1H NMR (400 MHz, DMSO) δ 7.47 – 7.33 (m, 9H), 7.26 (d, J = 
1.4 Hz, 1H), 7.15 – 7.05 (m, 6H), 6.62 – 6.57 (s, 1H), 4.02 (q, J = 7.1 Hz, 2H), 2.43 (t, J = 7.4 Hz, 
2H), 2.25 (t, J = 7.4 Hz, 2H), 1.77 (m, 2H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 
172.8, 142.4, 140.3, 137.7, 129.2, 128.1, 127.9, 117.6, 74.3, 59.6, 32.8, 26.9, 24.2, 14.1. HRMS: 
m/z expected [M+Na]+ = 447.2049 found 447.1980. Characterisation data is in alignment with 
the literature.115 
 
3.1.4 – 6-methyl-[1,1’-biphenyl]-3-carbonitrile (3) 
 
3-bromo-4-methylbenzonitrile (1.0 g, 5.1 mmol) was dissolved in DMF/H2O (1:1, 17 mL). 
Under a nitrogen atmosphere was added phenylboronic acid (933 mg, 7.65 mmol), Cs2CO3 
(2.49 g, 7.65 mmol) and PdCl2(dppf)·DCM (416 mg, 0.51 mmol) to the reaction mixture. This 
was stirred at 90 °C for 14 h. The reaction was cooled to room temperature and diluted with 
EtOAc before filtering through celite to remove the Pd catalyst. The filtrate was poured into 
H2O and extracted with EtOAc (3 X). The organic layers were combined, washed with brine 
and dried by passing through a hydrophobic frit filter before being concentrated in vacuo. The 
crude residue was purified by flash chromatography, eluting at a gradient of 0-50% EtOAc in 
hexanes. The eluent was concentrated in vacuo to afford a white powder at 860 mg (87%).  
RF = 0.45 (EtOAc/hexanes 1:9). 1H NMR (400 MHz, DMSO) δ 7.71 (dd, J = 7.9, 1.8 Hz, 1H), 7.61 
(d, J = 1.8 Hz, 1H), 7.56 – 7.31 (m, 6H), 2.28 (s, 3H). 13C NMR (101 MHz, DMSO) δ 142.4, 141.2, 
139.0, 132.7, 131.5, 130.8, 128.9, 128.4, 127.7, 118.8, 108.93, 20.4. HRMS: m/z expected 
[M+Na]+ = 216.0788 found 216.0744. Characterisation data is in alignment with the 
literature.115 
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3.1.5 – 6-bromomethyl-[1,1’-biphenyl]-3-carbonitrile (4) 
 
To a solution of 3 (800 mg, 4.1 mmol) in CCl4 (14 mL) was added NBS (873 mg, 4.72 mmol) 
and AIBN (67.3 mg, 0.41 mmol). This underwent microwave-assisted synthesis at 80 °C, 40W 
for 2 h with constant stirring. The reaction was cooled to room temperature and poured into 
H2O where it was extracted with DCM (3 X). The combined organic layers were washed with 
brine and passed through a hydrophobic frit to dry before being concentrated in vacuo. The 
crude residue was purified by flash chromatography, eluting at a gradient of 0-50% EtOAc in 
petroleum ether. The eluent was concentrated in vacuo to afford a viscous brown oil at 536 
mg (64%).  
 
RF = 0.58 (EtOAc/hexanes 1:9). 1H NMR (400 MHz, DMSO) δ 7.88 (dd, J = 8.0, 1.8 Hz, 1H), 7.80 
(d, J = 8.1 Hz, 1H), 7.74 (d, J = 1.7 Hz, 1H), 7.58 – 7.38 (m, 5H), 4.62 (s, 2H). 13C NMR (101 MHz, 
DMSO) δ 142.5, 140.6, 137.7, 133.8, 132.1, 131.6, 128.7, 128.6, 128.2, 118.3, 111.4, 31.2. 
HRMS: m/z expected [M+Na]+ = 295.9895 found 295.9853. Characterisation data is in 
alignment with the literature.115 
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3.1.6 – Ethyl-4-(1-((5-cyano-[1,1’-biphenyl]-2-yl)methyl)-1H-imidazol-5-yl) butanoate (5) 
 
Ethyl 4-(1-trityl-1H-imidazol-4-yl)butanoate (2) (89 mg, 0.21 mmol) was dissolved in MeCN 
(2.2 mL) before the subsequent addition of 6-Bromomethyl-[1,1’-biphenyl]-3-carbonitrile (4) 
(50 mg, 1.8 mmol). The reaction mixture was stirred at room temperature for 15 h. The 
reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (1.5 mL). 
The reaction was heated to 70 °C and stirred for 3 h. The reaction mixture was cooled to room 
temperature and then concentrated in vacuo before dissolving in DCM and washing in 
saturated NaHCO3 solution (3 X). The combined organic layers were washed with brine and 
passed through a hydrophobic frit filter to dry. The crude residue was concentrated in vacuo 
and purified by flash chromatography, eluting at a gradient of 0-10% MeOH in DCM. The 
eluent was concentrated to afford a yellow powder at 45 mg (57%).  
 
RF = 0.6 (MeOH/DCM 0.5:9.5). 1H NMR (400 MHz, DMSO) δ 7.82 (dd, J = 8.1, 1.8 Hz, 1H), 7.76 
(d, J = 1.8 Hz, 1H), 7.56 – 7.38 (m, 5H), 7.08 – 6.59 (m, 2H), 5.15 (s, 2H), 3.98 (q, J = 7.1 Hz, 2H), 
2.16 (dt, J = 12.1, 7.5 Hz, 4H), 1.60 – 1.48 (m, 2H), 1.12 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
DMSO) δ 172.4, 141.5, 140.4, 137.6, 133.4, 131.7, 128.9, 128.7, 128.4, 128.3, 128.2, 127.7, 
126.1, 118.4, 110.6, 59.7, 45.4, 32.7, 23.0, 22.3, 14.1. HRMS: m/z expected [M+H]+ = 374.1790 
found 374.1817. Characterisation data is in alignment with the literature.115 
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4.2 – Molecular Docking 
 
Peptide models were generated using Schrödinger Bioluminate.159–161 3D models of peptides 
conjugated to CSN5i-3 were created within UCSF Chimera.162 All other 3D ligand models were 
generated in Schrödinger Maestro.159–161 All ligands were energy minimised within 
Schrödinger Maestro using the LigPrep tool. The active site model was achieved by importing 
the structure of CSN5 bound to the ligand CSNi-3 (PDB: 5JOG) to Schrödinger Maestro and 
removing the ligand to produce an unbound model of CSN5 in its active form. The protein was 
further prepared by adding hydrogens and removing waters using the Protein Preparation 
wizard in Schrödinger Maestro. Molecular docking of the ligands to active-form CSN5 was 
performed in Schrödinger Glide using a constraint for the interaction with the active site Zn2+ 
atom. Following docking, the resulting poses were scored using Glidescore2 which ranks the 
poses in order of binding affinity and the top scoring poses were selected for visualisation. 3D 
figures of the poses were generated in UCSF Chimera. 2D ligand interaction analysis diagrams 
were produced in Schrödinger Maestro. 
 
4.3 – Peptide Synthesis 
 
4.3.1 – General Information 
 
All Fmoc-protected amino acids were purchased from either CEM Corporation or Pepceuticals 
Ltd. Fmoc-pseudoproline dipeptides, Fmoc-Gly NovaSyn TGT resin and H-Gly 2-chlorotrityl 
resin were purchased from Sigma-Aldrich. Peptide-grade DMF was purchased from 
Cambridge Reagents Limited and HCTU from Pepceuticals Ltd. All other reagents were 
purchased from Sigma-Aldrich and used without any further purification. All glassware was 
dried at 110°C for at least 14 hours and cooled in a desiccator before use. Unless otherwise 
stated, all DMF used in this section is of peptide grade. 
 
All peptide synthesis was performed on a Biotage® Initiator+ Alstra™ automated microwave 
peptide synthesiser using Biotage® 10mL or 30mL reactor vials fitted with 
polytetrafluoroethylene (PTFE) frit filters. Analytical HPLC of peptides was performed on a 
Shimadzu reverse-phase HPLC with UV-vis detection (monitoring at 214 nm and 280 nm) using 
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a Gemini™ C18 (5µm, 110Å, 150 mm × 4.6 mm) column at a flow rate of 1 mL/min. A solvent 
system of H2O + 0.1% TFA (buffer A) and 95% acetonitrile + 0.1% TFA (buffer B) was utilised 
for analytical HPLC at a linear gradient of 0-100% buffer B over 50 minutes. Column retention 
time (Rt) is reported in minutes. Liquid chromatography mass spectrometry (LC-MS) was 
carried out using a Dionex Ultimate 3000 LC fitted to a Thermo Scientific LCQ Fleet quadrupole 
mass spectrometer using electrospray ionisation in positive mode (ESI+) with a C18 column 
(2.1 x 50 mm). A solvent system of H2O + 0.1% TFA (buffer A) and 95% acetonitrile + 0.1% TFA 
(buffer B) was utilised with a linear gradient of 5-100% buffer B over 20 minutes at a flow rate 
of 0.6 mL/min. High resolution mass spectrometry was performed on a Bruker microTOF-Q II 
using ESI+. Solvent evaporation was performed under reduced pressure on a Heidolph rotary 
evaporator. Peptide lyophilisation was carried out using a Christ Alpha 2-4 LDplus freeze 
dryer. 
 
Resin swelling was performed in DCM for 20 mins at room temperature. Room temperature 
coupling of standard Fmoc-protected amino acids was carried out for 60 mins in an 
automated peptide synthesiser. Microwave-assisted coupling of standard amino acids was 
performed at 70°C for 10 mins. Double coupling refers to the coupling of a residue proceeded 
by DMF washing 4 times before repeating the coupling procedure with fresh reagents. All 
arginine residues were double-coupled at room temperature for 60 mins and then at 70°C for 
a further 5 mins. All histidine residues were coupled at room temperature for 5 mins and 
subsequently at 50°C for a further 5 mins. HCTU was dissolved in DMF at a 0.5 M 
concentration and DIEA was dissolved in NMP at either a 1 M or 2 M concentration. Fmoc 
deprotection was performed using 20% piperidine in DMF + 5% formic acid at room 
temperature for 5 mins followed by an additional 3 mins at 70°C.  
 
Test cleavage was carried out using a cleavage cocktail of 95% TFA, 2.5% TIS and 2.5% H2O. 1 
mL of the cleavage cocktail was added to a small sample of resin and shaken for 1 hour at 
room temperature. The solvent was filtered through a PTFE frit filter, collected into a Falcon 
tube and the TFA was evaporated using a stream of nitrogen gas. The peptide was 
subsequently precipitated in ice-cold Et2O and centrifuged at 3500 x g for 5 mins. The 
supernatant was discarded and the pellet was washed with Et2O three times. The pellet was 
resuspended in a mixture of acetonitrile and water before subsequent analysis. 
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4.3.2 – Attempted NEDD8 Synthesis 
 
Synthesis of the full NEDD8 protein was performed on Fmoc-Gly NovaSyn TGT resin at a 0.05 
mmol scale using a Biotage® 10 mL reactor vial. All amino acids were dissolved in DMF at a 
0.12 M concentration. Coupling of standard Fmoc-protected amino acids was carried out 
using 5 Eq and pseudoproline dipeptide coupling using 2.5 Eq. 5 Eq HCTU and 10 Eq 1 M DIEA 
were used for the coupling. Due to the relatively small scale of the reaction, an excess of 
reagents were used to increase the reaction volume to accommodate the 10 mL reactor vial. 
Coupling of the first 3 residues (LRG) was performed at room temperature and all subsequent 
couplings were carried out with microwave assistance, as described in Chapter 4.3.1. After 
coupling of 32 residues, all subsequent residues were double coupled. Fmoc deprotection 
was performed using 20% piperidine in DMF + 5% formic acid, as described in Chapter 4.3.1. 
 
Test cleavage was performed using a cleavage cocktail of 95% TFA, 2.5% TIS and 2.5% H2O, as 
described in Chapter 4.3.1. 
 
4.3.3 – Diketopiperazine Test 
 
Synthesis of the diglycine dipeptide was performed on Fmoc-Gly NovaSyn TGT resin at a 0.05 
mmol scale using a Biotage® 10 mL reactor vial. The Fmoc-protected glycine was dissolved in 
DMF at a 0.12 M concentration. Coupling and deprotection was performed as described in 
Chapter 4.3.2. After deprotection of the N-terminal glycine, a sample of the 20% 
piperidine/DMF solution was collected and filtered through a PTFE frit filter before analysis 
by HRMS. 
 
4.3.4 – NEDD8 C-terminal 12-mer Peptide Synthesis 
 
The 12-mer peptide was synthesised using H-Gly 2-chlorotrityl resin at a 0.3 mmol scale using 
a Biotage® 30 mL reactor vial. All amino acids were dissolved in DMF at a 0.2 M concentration 
and coupled using 4 Eq. 4 Eq HCTU and 8 Eq 2M DIEA were used for coupling. All residues 
were coupled at room temperature or as specified in Chapter 4.3.1. Fmoc deprotection was 
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performed using 20% piperidine in DMF + 5% formic acid, as described in Chapter 4.3.1. D-
Biotin was dissolved in DMSO at a 0.2 M concentration and 4 Eq was coupled onto the N-
terminus of the peptide using 4 Eq HCTU and 8 Eq 2M DIEA. The biotin coupling was 
performed at room temperature for 60 minutes. Upon completion of the synthesis, the resin-
bound peptide was washed with DMF 4 times for 45s and then washed again with DCM 4 
times for 45s.  
 
Test cleavage was carried out using a cleavage cocktail of 95% TFA, 2.5% TIS and 2.5% H2O, as 
described in Chapter 4.3.1. Full cleavage of the peptide from resin whilst ensuring it remains 
fully protected was performed using 10mL 1% TFA in DCM. This was stirred for 3 hours before 
the solvent was filtered through a PTFE frit filter and collected in a round-bottom flask. The 
peptide was concentrated by rotary evaporation and dissolved in a solution of acetic acid, 
acetonitrile and H2O. The peptide was subsequently lyophilised to yield a light-yellow powder. 
 
4.3.5 – Attempted Peptide Conjugation to Hydroxylamine 
 
NEDD8 C-terminal 12-mer peptide (50 mg, 0.35 mmol) was dissolved in 5 mL DMF and cooled 
to 0°C on ice. O-tert-butyl hydroxyl amine hydrochloride (67 mg, 0.53 mmol, 1.5 equiv) was 
added to the solution under nitrogen atmosphere followed by DMAP (9 mg, 0.07 mmol) and 
was stirred for 5 mins at 0°C. DCC (110 mg, 0.54 mmol) was added to the mixture and allowed 
to stir at room temperature for 20h. The solvent was removed in vacuo by rotary evaporation 
and the crude product was dissolved in acetonitrile/H2O before analysis by LC-MS and 
analytical HPLC. 
 
4.3.6 – Attempted Peptide Conjugation to Imidazole 
 
To a solution of NEDD8 C-terminal 12-mer peptide (30 mg, 0.21 mmol) in 4 mL DMF was added 
N,N’- Carbonyldiimidazole (44 mg, 0.27 mmol). The mixture was stirred at room temperature 
for 3h before the addition of Et3N (0.038 mL, 0.27 mmol). The mixture was subsequently 
stirred for a further 14h at room temperature. The solvent was removed in vacuo by rotary 
evaporation and the crude product was dissolved in acetonitrile/H2O before analysis by LC-
MS and analytical HPLC. 
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Appendix 
 
Figure S1: 1H NMR (400 MHz, CDCl3) of 4-iodo-1-trityl-1H-imidazole (1) 
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Figure S2: 13C NMR (101 MHz, CDCl3) of 4-iodo-1-trityl-1H-imidazole (1) 
 
 
Figure S3: 1H NMR (400 MHz, DMSO) of Ethyl 4-(1-trityl-1H-imidazol-4-yl)butanoate (2) 
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Figure S4: 13C NMR (101 MHz, DMSO) of Ethyl 4-(1-trityl-1H-imidazol-4-yl)butanoate (2) 
 
 
Figure S5: 1H NMR (400 MHz, DMSO) of 6-Methyl-[1,1’-biphenyl]-3-carbonitrile (3) 
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Figure S6: 13C NMR (101 MHz, DMSO) of 6-Methyl-[1,1’-biphenyl]-3-carbonitrile (3) 
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Figure S7: 1H NMR (400 MHz, DMSO) of 6-Bromomethyl-[1,1’-biphenyl]-3-carbonitrile (4) 
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Figure S8: 13C NMR (101 MHz, DMSO) of 6-Bromomethyl-[1,1’-biphenyl]-3-carbonitrile (4) 
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Figure S9: 1H NMR (400 MHz, DMSO) of Ethyl-4-(1-((5-cyano-[1,1’-biphenyl]-2-yl)methyl)-1H-
imidazol-5-yl) butanoate (5) 
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Figure S10: 13C NMR (101 MHz, DMSO) of Ethyl-4-(1-((5-cyano-[1,1’-biphenyl]-2-yl)methyl)-
1H-imidazol-5-yl) butanoate (5) 
 
Diketopiperazine formation 
 
Figure S11: ESI+ HRMS of diketopiperazine (cyclic diglycine dipeptide). m/z expected [M+H]+ 
= 114, found 114. m/z expected [M+Na]+ = 136, found 136. 
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NEDD8 Synthesis: Test Cleave 1 
 
Figure S12: LC-MS of NEDD8 residues 52-76 + Fmoc. m/z expected [M/3] = 940, found 940. 
m/z expected [M/2] = 1410, found 1410. 
 
 
Figure S13: Analytical HPLC of crude NEDD8 residues 52-76 + Fmoc. Rt of product at 42 min. 
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NEDD8 Synthesis: Test cleave 2 
 
 
 
Figure S14: LC-MS of NEDD8 residues 25-76. m/z expected [M/6] = 973, found 973. m/z 
expected [M/5] = 1167, found 1168. m/z expected [M/4] = 1459, found 1459. 
 
 
Figure S15: Analytical HPLC of crude NEDD8 residues 25-76 + Fmoc. Rt of product at 39.5 min. 
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NEDD8 Synthesis: Test cleave 3 
 
 
Figure S16: LC-MS of NEDD8 residues 1-76 + Fmoc. m/z expected [M] = 8782, not found. m/z 
found = 7224 (by ESI calculation). 
 
 
 
Figure S17: Analytical HPLC of crude NEDD8 residues 1-76 + Fmoc. Rt of observed mass = 39 
min. 
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Biotinylated 12-mer NEDD8 C-terminal Peptide 
 
 
Figure S18: ESI+ HRMS of SVLHLVLALRGG + biotin. m/z expected [M+H]+ = 1461, found 1461. 
 
 
Figure S19: Analytical HPLC of crude SVLHLVLALRGG + biotin. Rt of product = 14.5 min. 
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Conjugation of 12-mer Peptide to Hydroxylamine 
  
Figure S20: LC-MS of biotin-SVLHLVLALRGG + hydroxylamine. m/z expected [M] = 1476, not 
found. 
 
 
Figure S21: Analytical HPLC of crude biotin-SVLHLVLALRGG + hydroxylamine. Rt of observed 
mass = 14.5 min 
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Conjugation of 12-mer Peptide to Imidazole 
 
Figure S22: LC-MS of biotin-SVLHLVLALRGG + imidazole. m/z expected [M] = 1512, not found. 
 
 
Figure S23: Analytical HPLC of crude biotin-SVLHLVLALRGG + imidazole. Rt of observed mass 
= 15 min. 
 
 
